

# WALGREENS BOOTS ALLIANCE, INC.

## FORM 10-Q (Quarterly Report)

Filed 06/29/17 for the Period Ending 05/31/17

Address	108 WILMOT ROAD DEERFIELD, IL 60015
Telephone	(847) 315-2500
CIK	0001618921
Symbol	WBA
SIC Code	5912 - Drug Stores and Proprietary Stores
Fiscal Year	08/31

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549  
**FORM 10-Q**

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the Quarterly Period Ended May 31, 2017**

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number  
001-36759

**WALGREENS BOOTS ALLIANCE, INC.**

(Exact name of registrant as specified in its charter)

Delaware

(State of Incorporation)

47-1758322

(I.R.S. Employer Identification No.)

108 Wilmot Road, Deerfield, Illinois

(Address of principal executive offices)

60015

(Zip Code)

(847) 315-2500

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to the Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

The number of shares outstanding of the registrant's Common Stock, \$.01 par value, as of May 31, 2017 was 1,070,096,486 .

---

---

WALGREENS BOOTS ALLIANCE, INC.

FORM 10-Q FOR THE THREE AND NINE MONTHS ENDED MAY 31, 2017

**TABLE OF CONTENTS**

PART I. FINANCIAL INFORMATION

Item 1.	Consolidated Condensed Financial Statements (Unaudited)	
a)	<a href="#">Balance Sheets</a>	<a href="#">3</a>
b)	<a href="#">Statement of Equity</a>	<a href="#">4</a>
c)	<a href="#">Statements of Earnings</a>	<a href="#">5</a>
d)	<a href="#">Statements of Comprehensive Income</a>	<a href="#">6</a>
e)	<a href="#">Statements of Cash Flows</a>	<a href="#">7</a>
f)	<a href="#">Notes to Financial Statements</a>	<a href="#">9</a>
Item 2.	<a href="#">Management's discussion and analysis of financial condition and results of operations</a>	<a href="#">28</a>
Item 3.	<a href="#">Quantitative and qualitative disclosure about market risk</a>	<a href="#">48</a>
Item 4.	<a href="#">Controls and procedures</a>	<a href="#">48</a>

PART II. OTHER INFORMATION

Item 1.	<a href="#">Legal proceedings</a>	<a href="#">49</a>
Item 1A.	<a href="#">Risk factors</a>	<a href="#">49</a>
Item 2.	<a href="#">Unregistered sales of equity securities and use of proceeds</a>	<a href="#">50</a>
Item 6.	<a href="#">Exhibits</a>	<a href="#">51</a>

## Part I. Financial Information

Item 1. Consolidated Condensed Financial Statements (Unaudited)

**WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES**  
**CONSOLIDATED CONDENSED BALANCE SHEETS**  
**(UNAUDITED)**  
(in millions, except shares and per share amounts)

	<u>May 31, 2017</u>	<u>August 31, 2016</u>
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 12,253	\$ 9,807
Accounts receivable, net	6,339	6,260
Inventories	8,681	8,956
Other current assets	879	860
Total current assets	<u>28,152</u>	<u>25,883</u>
<b>Non-current assets:</b>		
Property, plant and equipment, net	13,535	14,335
Goodwill	15,516	15,527
Intangible assets, net	10,208	10,302
Equity method investments (see note 4)	6,323	6,174
Other non-current assets	439	467
Total non-current assets	<u>46,021</u>	<u>46,805</u>
<b>Total assets</b>	<b><u>\$ 74,173</u></b>	<b><u>\$ 72,688</u></b>
<b>Liabilities and equity</b>		
<b>Current liabilities:</b>		
Short-term borrowings	\$ 4,838	\$ 323
Trade accounts payable (see note 18)	11,528	11,000
Accrued expenses and other liabilities	5,065	5,484
Income taxes	282	206
Total current liabilities	<u>21,713</u>	<u>17,013</u>
<b>Non-current liabilities:</b>		
Long-term debt	14,372	18,705
Deferred income taxes	2,403	2,644
Other non-current liabilities	4,201	4,045
Total non-current liabilities	<u>20,976</u>	<u>25,394</u>
<b>Commitments and contingencies</b>		
<b>Equity:</b>		
Preferred stock \$.01 par value; authorized 32 million shares, none issued	—	—
Common stock \$.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at May 31, 2017 and August 31, 2016	12	12
Paid-in capital	10,389	10,111
Employee stock loan receivable	—	(1)
Retained earnings	29,744	27,684
Accumulated other comprehensive loss	(3,303)	(2,992)
Treasury stock, at cost; 102,417,132 shares at May 31, 2017 and 89,527,027 at August 31, 2016	(6,242)	(4,934)
Total Walgreens Boots Alliance, Inc. shareholders' equity	<u>30,600</u>	<u>29,880</u>
Noncontrolling interests	884	401
Total equity	<u>31,484</u>	<u>30,281</u>
<b>Total liabilities and equity</b>	<b><u>\$ 74,173</u></b>	<b><u>\$ 72,688</u></b>

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.



**WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES**  
**CONSOLIDATED CONDENSED STATEMENT OF EQUITY**  
**(UNAUDITED)**  
**For the nine months ended May 31, 2017**  
**(in millions, except shares)**

**Equity attributable to Walgreens Boots Alliance, Inc.**

	Common stock shares	Common stock amount	Treasury stock amount	Paid-in capital	Employee stock loan receivable	Accumulated other comprehensive (loss) income	Retained earnings	Noncontrolling interests	Total equity
August 31, 2016	1,082,986,591	\$ 12	\$ (4,934)	\$ 10,111	\$ (1)	\$ (2,992)	\$ 27,684	\$ 401	\$ 30,281
Net earnings	—	—	—	—	—	—	3,276	18	3,294
Other comprehensive income (loss), net of tax	—	—	—	—	—	(311)	—	(38)	(349)
Dividends declared	—	—	—	—	—	—	(1,216)	(12)	(1,228)
Treasury stock purchases	(17,419,955)	—	(1,457)	—	—	—	—	—	(1,457)
Employee stock purchase and option plans	4,529,850	—	149	26	1	—	—	—	176
Stock-based compensation	—	—	—	71	—	—	—	—	71
Noncontrolling interests acquired and arising on business combinations	—	—	—	181	—	—	—	515	696
May 31, 2017	1,070,096,486	\$ 12	\$ (6,242)	\$ 10,389	\$ —	\$ (3,303)	\$ 29,744	\$ 884	\$ 31,484

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.

**WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES**  
**CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS**  
**(UNAUDITED)**  
(in millions, except per share amounts)

	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Sales	\$ 30,118	\$ 29,498	\$ 88,065	\$ 88,715
Cost of sales	22,973	22,065	66,243	65,996
Gross profit	7,145	7,433	21,822	22,719
Selling, general and administrative expenses	5,712	5,903	17,522	17,861
Equity earnings in AmerisourceBergen	84	3	143	3
Operating income	1,517	1,533	4,443	4,861
Other income (expense)	(8)	28	(22)	(525)
Earnings before interest and income tax provision	1,509	1,561	4,421	4,336
Interest expense, net	155	147	500	425
Earnings before income tax provision	1,354	1,414	3,921	3,911
Income tax provision	168	322	634	790
Post tax earnings from other equity method investments	(21)	15	7	35
Net earnings	1,165	1,107	3,294	3,156
Net earnings attributable to noncontrolling interests	3	4	18	13
Net earnings attributable to Walgreens Boots Alliance, Inc.	\$ 1,162	\$ 1,103	\$ 3,276	\$ 3,143
Net earnings per common share:				
Basic	\$ 1.08	\$ 1.02	\$ 3.03	\$ 2.90
Diluted	\$ 1.07	\$ 1.01	\$ 3.02	\$ 2.88
Dividends declared per share	\$ 0.375	\$ 0.360	\$ 1.125	\$ 1.080
Weighted average common shares outstanding:				
Basic	1,077.1	1,080.8	1,079.6	1,083.3
Diluted	1,082.6	1,088.2	1,085.5	1,091.7

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.

**WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES**  
**CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME**  
**(UNAUDITED)**  
**(in millions)**

	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Comprehensive income:				
Net earnings	\$ 1,165	\$ 1,107	\$ 3,294	\$ 3,156
Other comprehensive income (loss), net of tax:				
Pension/postretirement obligations	5	3	1	4
Unrealized gain on cash flow hedges	1	—	3	2
Unrecognized loss on available-for-sale investments	(1)	(172)	(2)	(259)
Share of other comprehensive loss of equity method investments	2	—	(3)	—
Currency translation adjustments	504	769	(348)	(837)
Total other comprehensive income (loss)	511	600	(349)	(1,090)
Total comprehensive income (loss)	1,676	1,707	2,945	2,066
Comprehensive income (loss) attributable to noncontrolling interests	8	12	(20)	(15)
Comprehensive income (loss) attributable to Walgreens Boots Alliance, Inc.	\$ 1,668	\$ 1,695	\$ 2,965	\$ 2,081

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.



**WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES**  
**CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS**  
**(UNAUDITED)**  
**(in millions)**

	Nine months ended	
	May 31, 2017	May 31, 2016
<b>Cash flows from operating activities :</b>		
Net earnings	\$ 3,294	\$ 3,156
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	1,244	1,271
Change in fair value of warrants and related amortization	—	845
Deferred income taxes	(211)	(250)
Stock compensation expense	71	87
Equity earnings from equity method investments	(150)	(38)
Other	289	(14)
Changes in operating assets and liabilities:		
Accounts receivable, net	(153)	8
Inventories	259	(481)
Other current assets	22	21
Trade accounts payable	821	686
Accrued expenses and other liabilities	(268)	(247)
Income taxes	6	135
Other non-current assets and liabilities	13	10
Net cash provided by operating activities	<u>5,237</u>	<u>5,189</u>
<b>Cash flows from investing activities :</b>		
Additions to property, plant and equipment	(912)	(904)
Proceeds from sale leaseback transactions	436	60
Proceeds from sale of businesses	—	68
Proceeds from sale of other assets	39	116
Business and intangible asset acquisitions, net of cash acquired	(63)	(115)
Investment in AmerisourceBergen	—	(1,169)
Other	48	(17)
Net cash used for investing activities	<u>(452)</u>	<u>(1,961)</u>
<b>Cash flows from financing activities :</b>		
Proceeds and payments from short-term borrowings, net	277	(658)
Payments of long-term debt	(40)	(31)
Stock purchases	(1,457)	(1,152)
Proceeds related to employee stock plans	174	175
Cash dividends paid	(1,228)	(1,174)
Other	(59)	(54)
Net cash used for financing activities	<u>(2,333)</u>	<u>(2,894)</u>
Effect of exchange rate changes on cash and cash equivalents	(6)	(43)
<b>Changes in cash and cash equivalents :</b>		

Net increase in cash and cash equivalents	2,446	291
Cash and cash equivalents at beginning of period	9,807	3,000
Cash and cash equivalents at end of period	<u>\$ 12,253</u>	<u>\$ 3,291</u>

The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements.

**WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES**  
**NOTES TO FINANCIAL STATEMENTS**  
**(UNAUDITED)**

**Note 1. Accounting policies**

**Basis of presentation**

The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned subsidiaries in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated.

The Consolidated Condensed Balance Sheets as of May 31, 2017 and August 31, 2016, the Consolidated Condensed Statements of Equity for the nine months ended May 31, 2017, the Consolidated Condensed Statements of Cash Flows for the nine months ended May 31, 2017 and May 31, 2016, the Consolidated Condensed Statements of Earnings and the Consolidated Condensed Statements of Comprehensive Income for the three and nine months ended May 31, 2017 and May 31, 2016 are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2016. The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there were no subsequent events to disclose other than as disclosed in notes 1, 7 and 10.

In the opinion of the Company, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. The influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any period may not be comparable to the same period in previous years. With respect to the Company’s Retail Pharmacy USA segment, the positive impact on gross margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion.” In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on the Company’s Retail Pharmacy USA segment’s sales, gross margin and gross profit dollars making the Company’s operations or net earnings for any period incomparable.

To improve comparability, certain classification changes were made to prior periods to conform to current year classifications. These reclassifications were made in the fourth quarter of fiscal 2016.

***Terminated acquisition of Rite Aid Corporation (“Rite Aid”) and related matters***

On October 27, 2015, Walgreens Boots Alliance entered into an Agreement and Plan of Merger with Rite Aid and Victoria Merger Sub, Inc., a wholly-owned subsidiary of Walgreens Boots Alliance (as amended as described below, the “Merger Agreement”), pursuant to which the Company agreed, subject to the terms and conditions thereof, to acquire Rite Aid, a drugstore chain in the United States. The Merger Agreement was amended by Amendment No. 1 thereto on January 29, 2017.

In connection with regulatory review of the merger contemplated by the Merger Agreement, on December 20, 2016, Walgreens Boots Alliance and Rite Aid announced that they had entered into an agreement (the “Fred’s Asset Purchase Agreement”), subject to the terms and conditions thereof, to sell certain Rite Aid stores and certain assets related to store operations to Fred’s, Inc. (“Fred’s”) for \$950 million in an all-cash transaction. The transaction was subject to the approval and completion of the acquisition of Rite Aid by Walgreens Boots Alliance pursuant to the Merger Agreement.

On June 28, 2017, Walgreens Boots Alliance and Rite Aid entered into a mutual termination agreement (the “Termination Agreement”) pursuant to which the parties agreed to terminate the Merger Agreement, including all schedules and exhibits thereto, and all ancillary agreements contemplated thereby, or entered pursuant thereto (other than as expressly specified) (collectively with the Merger Agreement, the “Transaction Documents”), effective as of June 28, 2017. Pursuant to the Termination Agreement, the Company agreed to pay Rite Aid the termination fee of \$325 million, which amount the Company plans to pay on or before June 30, 2017 in full satisfaction of any amounts required to be paid by the Company under the Merger Agreement and other Transaction Documents. The parties also agreed to release each other from, among other things,

any and all liability, claims, rights, actions, causes of action, damages, expenses and fees, however arising, in connection with, arising out of or related to the Transaction Documents, the transactions contemplated therein or thereby or certain related matters.

On June 28, 2017, following the termination of the Merger Agreement, the Fred’s Asset Purchase Agreement was terminated. In connection with the termination of the Fred’s Asset Purchase Agreement, the Company agreed to reimburse certain of Fred’s transaction costs in an amount not to exceed \$25 million in full satisfaction of any amounts required to be paid by the Company under the Fred’s Asset Purchase Agreement. The Company expects to pay the applicable amount during the fourth quarter of fiscal 2017.

See note 7, Borrowings and note 10, Commitments and contingencies for additional information relating to the termination of the Merger Agreement and related matters.

**Pending acquisition of certain Rite Aid assets**

On June 28, 2017, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Rite Aid, pursuant to which the Company agreed, subject to the terms and conditions thereof, to acquire 2,186 stores, three distribution centers and related inventory from Rite Aid. The consideration for the transaction will be \$5.175 billion in cash, the assumption by the Company of the related real estate leases and the grant of an option to Rite Aid, exercisable through May 2019 and subject to certain conditions, to become a member of the Company’s group purchasing organization, Walgreens Boots Alliance Development GmbH. The Company will also assume certain limited store-related liabilities as part of the transaction.

The transaction is subject to the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions. The initial closing is expected to occur within the next six months. Upon the initial closing of the transaction, the Company will begin acquiring the stores and related assets on a phased basis.

**Note 2. Restructuring**

On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the “Cost Transformation Program”) as part of an initiative to reduce costs and increase operating efficiencies. The Cost Transformation Program implemented and built on the cost-reduction initiative previously announced by the Company on August 6, 2014 and included plans to close stores across the U.S.; reorganize corporate and field operations; drive operating efficiencies; and streamline information technology and other functions. The actions under the Cost Transformation Program focus primarily on the Retail Pharmacy USA segment. From inception through May 31, 2017, the Company incurred pre-tax charges of \$1.6 billion ( \$677 million related to asset impairment charges, \$557 million in real estate costs and \$324 million in severance and other business transition and exit costs) related to the Cost Transformation Program, which are primarily recorded within selling, general and administrative expenses. Restructuring charges are recognized as the costs are incurred in accordance with GAAP.

Restructuring costs by segment are as follows (in millions):

	<b>Retail Pharmacy USA</b>	<b>Retail Pharmacy International</b>	<b>Pharmaceutical Wholesale</b>	<b>Walgreens Boots Alliance, Inc.</b>
<b>Three months ended May 31, 2017</b>				
Asset impairments	\$ 96	\$ 18	\$ —	\$ 114
Real estate costs	15	—	—	15
Severance and other business transition and exit costs	18	8	16	42
Total restructuring costs	<u>\$ 129</u>	<u>\$ 26</u>	<u>\$ 16</u>	<u>\$ 171</u>
<b>Three months ended May 31, 2016</b>				
Asset impairments	\$ 48	\$ —	\$ —	\$ 48
Real estate costs	—	—	—	—
Severance and other business transition and exit costs	12	6	7	25
Total restructuring costs	<u>\$ 60</u>	<u>\$ 6</u>	<u>\$ 7</u>	<u>\$ 73</u>

	<b>Retail Pharmacy USA</b>	<b>Retail Pharmacy International</b>	<b>Pharmaceutical Wholesale</b>	<b>Walgreens Boots Alliance, Inc.</b>
<b>Nine months ended May 31, 2017</b>				
Asset impairments	\$ 207	\$ 21	\$ 1	\$ 229
Real estate costs	264	—	—	264
Severance and other business transition and exit costs	46	30	23	99
Total restructuring costs	<u>\$ 517</u>	<u>\$ 51</u>	<u>\$ 24</u>	<u>\$ 592</u>
<b>Nine months ended May 31, 2016</b>				
Asset impairments	\$ 73	\$ —	\$ —	\$ 73
Real estate costs	52	—	—	52
Severance and other business transition and exit costs	45	14	7	66
Total restructuring costs	<u>\$ 170</u>	<u>\$ 14</u>	<u>\$ 7</u>	<u>\$ 191</u>

The changes in accrued expenses and other liabilities related to the Cost Transformation Program include the following (in millions):

	<b>Asset impairments</b>	<b>Real estate costs</b>	<b>Severance and other business transition and exit costs</b>	<b>Total</b>
<b>Balance at August 31, 2016</b>	\$ —	\$ 248	\$ 27	\$ 275
Restructuring costs	229	264	99	592
Payments	—	(51)	(80)	(131)
Other - non cash	(229)	—	—	(229)
Currency translation adjustments	—	—	—	—
<b>Balance at May 31, 2017</b>	<u>\$ —</u>	<u>\$ 461</u>	<u>\$ 46</u>	<u>\$ 507</u>

**Note 3. Operating leases**

Initial lease term for premises in the U.S. is typically 15 to 25 years, followed by additional terms containing renewal options at five -year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.

The Company continuously evaluates its real estate portfolio in conjunction with its capital needs. The Company has entered into several sale-leaseback transactions. For the nine months ended May 31, 2017 and May 31, 2016 , the Company recorded proceeds from sale-leaseback transactions of \$436 million and \$60 million , respectively. The Company has determined it no longer has continuing involvement related to these transactions and in accordance with the accounting standards related to sale-leaseback transactions has recognized any loss on sale immediately, any gain on sale was deferred and amortized over the life of the lease. Gains and losses are recorded within selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings.

The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. During the three and nine months ended May 31, 2017 , the Company recorded charges of \$25 million and \$289 million for facilities that were closed or relocated under long-term leases, including stores closed through the Company's restructuring activities. This compares to \$16 million and \$91 million for the three and nine months ended May 31, 2016 . These charges are reported in selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings.

[Table of Contents](#)

The changes in reserve for facility closings and related lease termination charges primarily in other non-current liabilities, include the following (in millions):

	<b>For the nine months ended May 31, 2017</b>	<b>For the twelve months ended August 31, 2016</b>
Balance at beginning of period	\$ 466	\$ 446
Provision for present value of non-cancellable lease payments on closed facilities	271	134
Assumptions about future sublease income, terminations and changes in interest rates	(7)	(34)
Interest accretion	25	27
Cash payments, net of sublease income	(100)	(107)
Balance at end of period	<u>\$ 655</u>	<u>\$ 466</u>

As of May 31, 2017, the Company remains secondarily liable on 70 leases. The maximum potential undiscounted future payments are \$330 million as of May 31, 2017.

**Note 4. Equity method investments**

Equity method investments as of May 31, 2017 and August 31, 2016, are as follows (in millions, except percentages):

	<b>May 31, 2017</b>		<b>August 31, 2016</b>	
	<b>Carrying value</b>	<b>Ownership percentage</b>	<b>Carrying value</b>	<b>Ownership percentage</b>
AmerisourceBergen	\$ 5,051	26%	\$ 4,964	24%
Others	1,272	8% - 50%	1,210	12% - 50%
Total	<u>\$ 6,323</u>		<u>\$ 6,174</u>	

*AmerisourceBergen investment*

As of May 31, 2017 and August 31, 2016, the Company owned 56,854,867 AmerisourceBergen Corporation ("AmerisourceBergen") common shares, representing approximately 26% and 24% of the outstanding AmerisourceBergen common stock, respectively. The Company accounts for its equity investment in AmerisourceBergen using the equity method of accounting, with the net earnings attributable to the Company's investment being classified within the operating income of its Pharmaceutical Wholesale segment. Due to the timing and availability of financial information of AmerisourceBergen, the Company accounts for this equity method investment on a financial reporting lag of two months. Equity earnings from AmerisourceBergen is reported as a separate line in the Consolidated Condensed Statements of Earnings. The level 1 fair market value of the Company's equity investment in AmerisourceBergen common stock at May 31, 2017 is \$5.2 billion.

The Company's investment in AmerisourceBergen carrying value exceeded its proportionate share of the net assets of AmerisourceBergen by \$4.4 billion. This premium of \$4.4 billion was recognized as part of the carrying value in the Company's equity investment in AmerisourceBergen. The difference was primarily related to goodwill and the fair value of AmerisourceBergen intangible assets.

*Other investments*

The Company's other equity method investments include its investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company's pharmaceutical wholesale investments in China; and the equity method investment retained through the sale of a majority interest in Option Care Inc. in fiscal 2015. The Company reported \$21 million of post-tax equity losses and \$15 million of post-tax equity earnings from equity method investments other than AmerisourceBergen for the three months ended May 31, 2017 and May 31, 2016, respectively. The Company reported \$7 million of post-tax equity earnings and \$35 million of post-tax equity earnings from equity method investments other than AmerisourceBergen for the nine months ended May 31, 2017 and May 31, 2016, respectively.

**Note 5. Acquisitions**

*AllianceRx Walgreens Prime*

On March 31, 2017, Walgreens Boots Alliance and pharmacy benefit manager Prime Therapeutics LLC ("Prime") closed a transaction to form a combined central specialty pharmacy and mail services company AllianceRx Walgreens Prime, as part of a strategic alliance. AllianceRx Walgreens Prime is consolidated by Walgreens Boots Alliance and reported within the Retail

Pharmacy USA division in its financial statements. The Company accounted for this acquisition of Prime’s specialty pharmacy and mail services business as a business combination involving noncash purchase consideration of \$720 million consisting of the issuance of an equity interest in AllianceRx Walgreens Prime.

As of May 31, 2017, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired and therefore the purchase price allocation has not been completed. The preliminary purchase price allocation will be subject to further refinement and may result in material changes. These changes will primarily relate to the allocation of consideration and the fair value assigned to all tangible and intangible assets acquired and identified. The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions).

	<b>May 31, 2017</b>
Total consideration	\$ 720
Identifiable assets acquired and liabilities assumed	
Accounts receivable, net	\$ 233
Inventories	149
Property, plant and equipment, net	11
Intangible assets, net	331
Trade accounts payable	(89)
Accrued expenses and other liabilities	(2)
<b>Total identifiable net assets</b>	<b>633</b>
Goodwill	\$ 87

The preliminary identified intangible assets primarily include payer contracts. These contracts are estimated to have a weighted average useful life of 15 years. The preliminary goodwill of \$87 million arising from the transaction consists of expected purchasing synergies, operating efficiencies by benchmarking performance and applying best practices across the combined company, consolidation of operations, reductions in selling, general and administrative expenses and combining workforces. Substantially all of the goodwill recognized is not expected to be deductible for income tax purposes.

In accordance with ASC Topic 810, Consolidation, the noncontrolling interest was recognized based on its proportionate interest in the identifiable net assets of AllianceRx Walgreens Prime. The difference between the carrying amount of the noncontrolling interest and the fair value recognized as consideration in the business combination is recognized as additional paid in capital.

The Company incurred legal and other professional services costs related to the transaction, which were included in selling, general and administrative expenses, of \$4 million and \$8 million, respectively, for the three and nine month periods ended May 31, 2017.

Pro forma net earnings and sales of the Company, assuming the acquisition had occurred at the beginning of each period presented, would not be materially different from the results reported. The acquisition did not have a material impact on net earnings or sales of the Company for the three and nine month periods ended May 31, 2017.

**Note 6. Goodwill and other intangible assets**

Changes in the carrying amount of goodwill by reportable segment consist of the following (in millions):

	<b>Retail Pharmacy USA</b>	<b>Retail Pharmacy International</b>	<b>Pharmaceutical Wholesale</b>	<b>Walgreens Boots Alliance, Inc.</b>
August 31, 2016	\$ 9,036	\$ 3,369	\$ 3,122	\$ 15,527
Acquisitions	87	—	—	87
Currency translation adjustments	—	(36)	(62)	(98)
May 31, 2017	<u>\$ 9,123</u>	<u>\$ 3,333</u>	<u>\$ 3,060</u>	<u>\$ 15,516</u>

The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):

	<b>May 31, 2017</b>	<b>August 31, 2016</b>
<b>Gross amortizable intangible assets</b>		
Customer relationships and loyalty card holders	\$ 1,830	\$ 1,867
Purchased prescription files	669	932
Favorable lease interests and non-compete agreements	536	619
Trade names and trademarks	502	532
Purchasing and payer contracts	390	94
Total gross amortizable intangible assets	<u>3,927</u>	<u>4,044</u>
<b>Accumulated amortization</b>		
Customer relationships and loyalty card holders	\$ 371	\$ 275
Purchased prescription files	376	600
Favorable lease interests and non-compete agreements	355	388
Trade names and trademarks	135	105
Purchasing and payer contracts	44	71
Total accumulated amortization	<u>1,281</u>	<u>1,439</u>
Total amortizable intangible assets, net	<u>\$ 2,646</u>	<u>\$ 2,605</u>
<b>Indefinite lived intangible assets</b>		
Trade names and trademarks	\$ 5,507	\$ 5,604
Pharmacy licenses	2,055	2,093
Total indefinite lived intangible assets	<u>\$ 7,562</u>	<u>\$ 7,697</u>
Total intangible assets, net	<u>\$ 10,208</u>	<u>\$ 10,302</u>

Amortization expense for intangible assets was \$98 million and \$287 million for the three and nine months ended May 31, 2017, and \$104 million and \$320 million for the three and nine months ended May 31, 2016, respectively.

Estimated annual amortization expense for intangible assets recorded at May 31, 2017 is as follows (in millions):

	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>
Estimated annual amortization expense	\$ 361	\$ 333	\$ 273	\$ 205	\$ 185



**Note 7. Borrowings**

Borrowings consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted)

	<u>May 31, 2017</u>	<u>August 31, 2016</u>
<b>Short-term borrowings</b> <sup>1</sup>		
<i>\$6 Billion note issuance</i> <sup>2,3</sup>		
1.750% unsecured notes due 2018	\$ 1,248	\$ —
2.600% unsecured notes due 2021	1,494	—
3.100% unsecured notes due 2023	745	—
<i>\$8 Billion note issuance</i> <sup>2,3</sup>		
1.750% unsecured notes due November 2017	749	—
<i>Unsecured Pound Sterling variable rate term loan due 2019</i>	105	63
<i>Other</i> <sup>4</sup>	497	260
<b>Total short-term borrowings</b>	<u>\$ 4,838</u>	<u>\$ 323</u>
<b>Long-term debt</b> <sup>1</sup>		
<i>Unsecured Pound Sterling variable rate term loan due 2019</i>	\$ 1,736	\$ 1,833
<i>\$6 Billion note issuance</i> <sup>2,3</sup>		
1.750% unsecured notes due 2018	—	1,246
2.600% unsecured notes due 2021	—	1,493
3.100% unsecured notes due 2023	—	744
3.450% unsecured notes due 2026	1,886	1,885
4.650% unsecured notes due 2046	590	590
<i>\$8 Billion note issuance</i> <sup>2,3</sup>		
1.750% unsecured notes due 2017	—	746
2.700% unsecured notes due 2019	1,246	1,244
3.300% unsecured notes due 2021	1,243	1,242
3.800% unsecured notes due 2024	1,988	1,987
4.500% unsecured notes due 2034	495	494
4.800% unsecured notes due 2044	1,492	1,492
<i>£700 Million note issuance</i> <sup>2,3</sup>		
2.875% unsecured Pound Sterling notes due 2020	513	521
3.600% unsecured Pound Sterling notes due 2025	384	391
<i>€750 Million note issuance</i> <sup>2,3</sup>		
2.125% unsecured Euro notes due 2026	838	830
<i>\$4 Billion note issuance</i> <sup>3,7</sup>		
3.100% unsecured notes due 2022	1,194	1,194
4.400% unsecured notes due 2042	492	492
<i>\$1 Billion note issuance</i> <sup>3,7</sup>		
5.250% unsecured notes due 2019 <sup>5</sup>	250	249
<i>Other</i> <sup>6</sup>	25	32
<b>Total long-term debt, less current portion</b>	<u>\$ 14,372</u>	<u>\$ 18,705</u>

<sup>1</sup> Carry values are presented net of unamortized discount and debt issuance costs, where applicable, and foreign currency denominated borrowings have been translated using the spot rates at May 31, 2017 and August 31, 2016, respectively.

<sup>2</sup> Notes are unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding.

- <sup>3</sup> The fair value and carrying value of the \$6 billion , \$8 billion , £0.7 billion , €0.75 billion , \$4 billion and \$1 billion note issuances as of May 31, 2017 was \$6.1 billion and \$6.0 billion , \$7.5 billion and \$7.2 billion , \$1.0 billion and \$0.9 billion , \$0.9 billion and \$0.8 billion , \$1.7 billion and \$1.7 billion , and \$0.3 billion and \$0.3 billion , respectively. The fair values of the notes outstanding are level 1 fair value measures and determined based on quoted market price and translated at the May 31, 2017 spot rate, as applicable.
- <sup>4</sup> Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various currencies.
- <sup>5</sup> Includes interest rate swap fair market value adjustments. See note 9, Fair value measurements for additional fair value disclosures.
- <sup>6</sup> Other long-term debt represents a mix of fixed and variable rate borrowings in various currencies with various maturities.
- <sup>7</sup> Notes are senior debt obligations of Walgreens and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance.

### **2017 Term Loan Credit Agreements**

On February 22, 2017, the Company entered into (a) a \$4.8 billion unsecured term loan facility with the lenders party thereto (the “Syndicated Credit Agreement”) and (b) a \$1.0 billion unsecured term loan facility with Sumitomo Mitsui Banking Corporation, as lender and administrative agent (the “Sumitomo Credit Agreement” and, together with the Syndicated Credit Agreement, the “2017 Term Loan Credit Agreements”). The obligations of the lenders party to each of the 2017 Term Loan Credit Agreements to fund the loans thereunder were to become effective upon the date of closing of the transactions contemplated by the Merger Agreement. Each of the 2017 Term Loan Credit Agreements and the commitments contemplated thereby terminated on June 28, 2017 upon the termination of the Merger Agreement. See note 1, Basis of presentation. As of May 31, 2017 , there were no borrowings under either of the 2017 Term Loan Credit Agreements.

### **2017 Revolving Credit Agreement**

On February 1, 2017, the Company entered into a \$1.0 billion revolving credit facility (the “2017 Revolving Credit Agreement”) with the lenders from time to time party thereto. The Company will be the borrower under the 2017 Revolving Credit Agreement, which terminates on the earlier of (a) 364 days following the effective date thereof, subject to the extension thereof pursuant to provisions specified in the Revolving Credit Agreement, and (b) the date of termination in whole of the aggregate commitment pursuant to the Revolving Credit Agreement. The ability of the Company to request the making of loans under the 2017 Revolving Credit Agreement is subject to the satisfaction (or waiver) of certain customary conditions set forth therein. As of May 31, 2017 , there were no borrowings under the 2017 Revolving Credit Agreement.

### **\$6.0 billion note issuance**

On June 1, 2016, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and offering expenses) of \$6.0 billion from a public offering of five series of U.S. dollar notes: \$1.2 billion of 1.750% notes due 2018 (the “2018 notes”), \$1.5 billion of 2.600% notes due 2021 (the “2021 notes”), \$0.8 billion of 3.100% notes due 2023 (the “2023 notes”), \$1.9 billion of 3.450% notes due 2026 (the “2026 notes”) and \$0.6 billion of 4.650% notes due 2046 (the “2046 notes”). Total issuance costs relating to the notes, including underwriting discounts and offering expenses, were \$30 million . The notes contain redemption terms which allow or require the Company to redeem the notes at defined redemption prices plus accrued and unpaid interest at redemption dates set forth in the applicable series of notes. Interest on the notes issued on June 1, 2016 is payable semi-annually. Because the merger with Rite Aid was not consummated on or prior to June 1, 2017, the 2018 notes, the 2021 notes and the 2023 notes (but not the 2026 notes or 2046 notes, which remain outstanding in accordance with their respective terms) were redeemed on June 5, 2017 under the special mandatory redemption terms of the indenture governing such notes. Walgreens Boots Alliance was required to redeem all of the 2018 notes, the 2021 notes and the 2023 notes then outstanding, at a special mandatory redemption price equal to 101% of the aggregate principal amount of such notes, plus accrued and unpaid interest of approximately \$1 million to, but excluding, the date of redemption. Accordingly, the 2018 notes, the 2021 notes and the 2023 notes were classified as Short-term borrowings on the Consolidated Condensed Balance Sheet as of May 31, 2017 .

### **Debt covenants**

The Company’s credit facilities contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 :1.00. The credit facilities contain various other customary covenants.

### **Other borrowings**

The Company periodically borrows under its commercial paper program. There were no commercial paper borrowings outstanding as of May 31, 2017 or August 31, 2016 , respectively. The Company had no activity under its commercial paper

program for the nine months ended May 31, 2017. The Company had average daily short-term borrowings of \$18 million of commercial paper outstanding at a weighted average interest rate of 0.66% for the nine month period ended May 31, 2016.

**Note 8. Financial instruments**

The Company uses derivative instruments to manage its exposure to interest rate and foreign currency exchange risks.

The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of May 31, 2017 and August 31, 2016 are as follows (in millions):

	May 31, 2017		August 31, 2016		Location in Consolidated Condensed Balance Sheets
	Notional <sup>1</sup>	Fair value	Notional <sup>1</sup>	Fair value	
<b>Derivatives designated as fair value hedges:</b>					
Interest rate swaps	\$ 250	\$ —	\$ —	\$ —	Other non-current liabilities
Interest rate swaps	—	—	250	3	Other non-current assets
<b>Derivatives not designated as hedges:</b>					
Foreign currency forwards	133	—	1,177	16	Other current assets
Foreign currency forwards	976	5	41	—	Accrued expenses and other liabilities
Basis swaps	2	—	—	—	Accrued expenses and other liabilities
Basis swaps	—	—	2	1	Other current assets

<sup>1</sup> Amounts are presented in U.S. dollar equivalents, as applicable.

The Company uses interest rate swaps to manage the interest rate exposure associated with some of its fixed-rate borrowings and designates them as fair value hedges. The Company uses forward starting interest rate swaps to hedge its interest rate exposure of some of its anticipated debt issuances.

The Company utilizes foreign currency forward contracts and other foreign currency derivatives to hedge significant committed and highly probable future transactions and cash flows denominated in currencies other than the functional currency of the Company or its subsidiaries. The Company has significant non-U.S. dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.

**Fair value hedges**

The Company holds interest rate swaps converting \$250 million of its 5.250% fixed rate notes to a floating interest rate based on the six-month LIBOR in arrears plus a constant spread. All swap termination dates coincide with the notes maturity date, January 15, 2019. These swaps were designated as fair value hedges.

The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were not material. The changes in fair value of the Company's debt that was swapped from fixed to variable rate and designated as fair value hedges are included in long-term debt on the Consolidated Condensed Balance Sheets (see note 7, Borrowings).

**Derivatives not designated as hedges**

The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of foreign currency risks. The gains and (losses) due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):

Location in Consolidated Condensed Statements of Earnings	Three months ended		Nine months ended		
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016	
Foreign currency forwards	Selling, general and administrative expenses	\$ (19)	\$ 24	\$ 28	\$ (1)
Foreign currency forwards	Other income (expense)	(1)	4	(15)	37

**Derivatives credit risk**

Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.

**Derivatives offsetting**

The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.

**Note 9. Fair value measurements**

The Company measures certain assets and liabilities in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to level 1 inputs.

Level 2 - Observable inputs other than quoted prices in active markets.

Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to level 3 inputs.

Assets and liabilities measured at fair value on a recurring basis are as follows (in millions):

	May 31, 2017	Level 1	Level 2	Level 3
<b>Assets :</b>				
Money market funds <sup>1</sup>	\$ 10,491	\$ 10,491	\$ —	\$ —
Available-for-sale investments <sup>2</sup>	1	1	—	—
Foreign currency forwards <sup>3</sup>	—	—	—	—
<b>Liabilities :</b>				
Foreign currency forwards <sup>3</sup>	5	—	5	—
Basis swaps <sup>3</sup>	—	—	—	—
Interest rate swaps <sup>4</sup>	—	—	—	—
	August 31, 2016	Level 1	Level 2	Level 3
<b>Assets :</b>				
Money market funds <sup>1</sup>	\$ 9,133	\$ 9,133	\$ —	\$ —
Available-for-sale investments <sup>2</sup>	32	32	—	—
Foreign currency forwards <sup>3</sup>	16	—	16	—
Interest rate swaps <sup>4</sup>	3	—	3	—
<b>Liabilities :</b>				
Basis swaps <sup>3</sup>	1	—	1	—

- <sup>1</sup> Money market funds are valued at the closing price reported by the fund sponsor.
- <sup>2</sup> Fair values of quoted investments are based on current bid prices as of the balance sheet dates.
- <sup>3</sup> The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
- <sup>4</sup> The fair value of interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See note 8, Financial instruments for additional information.

There were no transfers between levels for the three and nine months ended May 31, 2017 .

The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company's debt in the footnotes to the consolidated financial statements. Unless otherwise noted, the fair value for all notes was determined based upon quoted market prices and therefore categorized as level 1. See note 7, Borrowings for further information. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.

#### **Note 10. Commitments and contingencies**

##### *Litigation and regulatory proceedings*

The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, arising in the normal course of the Company's business, including the matters described below. Legal proceedings, in general, and securities and class action litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit, and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company's consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.

On a quarterly basis, the Company assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Company has determined that a loss is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company's assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Company's consolidated financial statements in a future fiscal period. Management's assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Company which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management's assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved.

On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co., and Walgreen Co. as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On April 10, 2015, the defendants filed a motion to dismiss. On May 18, 2015, the case was stayed in light of a securities class action that was filed on April 10, 2015. After a ruling issued on September 30, 2016 in the securities class action, which is described below, on November 3, 2016, the Court entered a stipulation and order extending the stay until the securities case is fully resolved.

On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. On June 16, 2015, the Court entered an order appointing a lead plaintiff. Pursuant to the Court's order, lead plaintiff filed an amended complaint on August 17, 2015, and defendants moved to dismiss the amended complaint on October 16, 2015. Lead plaintiff filed a response to the motion to dismiss on December 22, 2015, and defendants filed a reply in support of the motion on February 5, 2016. On September 30, 2016, the Court issued an order granting in part and denying in part defendants' motion to dismiss. Defendants filed their answer to the amended complaint on November 4, 2016 and filed an amended answer on January 16, 2017. Plaintiffs filed their motion for class certification on April 21, 2017. Briefing on the motion is scheduled to be completed by August 25, 2017.

As of May 31, 2017, the Company was aware of two putative class action lawsuits filed by purported Rite Aid stockholders against Rite Aid and its board of directors, Walgreens Boots Alliance and Victoria Merger Sub, Inc. for claims arising out of the transactions contemplated by the original Merger Agreement (prior to its amendment on January 29, 2017) (such transactions, the "Rite Aid Transactions"). One action was filed in the State of Pennsylvania in the Court of Common Pleas of Cumberland County (the "Pennsylvania action"), and one action was filed in the United States District Court for the Middle District of Pennsylvania (the "federal action"). The Pennsylvania action primarily alleged that the Rite Aid board of directors breached its fiduciary duties in connection with the Rite Aid Transactions by, among other things, agreeing to an unfair and inadequate price, agreeing to deal protection devices that preclude other bidders from making successful competing offers for Rite Aid, and failing to disclose all allegedly material information concerning the proposed merger, and also alleged that Walgreens Boots Alliance and Victoria Merger Sub, Inc. aided and abetted these alleged breaches of fiduciary duty. The federal action alleged, among other things, that Rite Aid and its board of directors disseminated an allegedly false and misleading proxy statement in connection with the Rite Aid Transactions. The plaintiffs in the federal action also filed a motion for preliminary injunction seeking to enjoin the Rite Aid shareholder vote relating to the Rite Aid Transactions. That motion was denied, and the Rite Aid shareholders approved the Rite Aid Transactions at a special meeting on February 4, 2016. In the federal action, plaintiffs agreed to stay the litigation until after the Rite Aid Transactions have closed, but on March 17, 2017, moved to lift the stay to allow plaintiffs to file an amended complaint. The Company filed a response opposing this motion, and the plaintiffs filed a reply in support of this motion on April 14, 2017. The Company was also named as a defendant in eight putative class action lawsuits filed in the Court of Chancery of the State of Delaware (the "Delaware actions"). Those actions were consolidated, and plaintiffs filed a motion for preliminary injunction seeking to enjoin the Rite Aid shareholder vote relating to the Rite Aid Transactions. That motion was denied and the plaintiffs in the Delaware actions agreed to settle this matter for an immaterial amount. The Delaware actions all have been dismissed.

#### *Terminated acquisition of Rite Aid and related matters*

On June 28, 2017, the Company and Rite Aid entered into the Termination Agreement pursuant to which the parties agreed to terminate the Merger Agreement and other Transaction Documents. Pursuant to the Termination Agreement, the Company agreed to pay Rite Aid the termination fee of \$325 million in full satisfaction of any amounts required to be paid by the Company under the Merger Agreement and other Transaction Documents. The Company plans to pay Rite Aid such fee on or before June 30, 2017. See note 1, Basis of presentation.

On June 28, 2017, following the termination of the Merger Agreement, the Fred's Asset Purchase Agreement was terminated. In connection with the termination of the Fred's Asset Purchase Agreement, the Company agreed to reimburse certain of Fred's transaction costs in an amount not to exceed \$25 million in full satisfaction of any amounts required to be paid by the Company under the Fred's Asset Purchase Agreement. The Company expects to pay the applicable amount during the fourth quarter of fiscal 2017. See note 1, Basis of presentation.

#### **Note 11. Retirement benefits**

The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan.

Effective September 1, 2016, for UK and U.S. benefit plans previously using the yield curve approach to establish discount rates, the Company changed the method used to calculate the service cost and interest cost components of net periodic benefit costs for pension and postretirement benefit plans and will measure these costs by applying the specific spot rates along the yield curve to the plans' projected cash flows. The Company believes the new approach provides a more precise measurement of service and interest costs by improving the correlation between projected cash flows and the corresponding spot yield curve rates. The change does not affect the measurement of the Company's pension and other postretirement benefit obligations for those plans and is accounted for as a change in accounting estimate, which is applied prospectively.

#### *Defined benefit pension plans (non-U.S. plans)*

The Company has various defined benefit pension plans outside the United States. The principal defined benefit pension plan is the Boots Pension Plan, which covers certain employees in the United Kingdom (the “Boots Plan”). The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis.

Components of net periodic pension costs for the defined benefit pension plans (in millions):

	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Service costs	\$ 1	\$ 1	\$ 3	\$ 3
Interest costs	43	77	129	236
Expected returns on plan assets/other	(41)	(62)	(112)	(189)
Total net periodic pension costs	\$ 3	\$ 16	\$ 20	\$ 50

The Company made cash contributions to its defined benefit pension plans of \$48 million for the nine months ended May 31, 2017, which primarily related to committed funded payments. The Company plans to contribute an additional \$18 million to its defined benefit pension plans in fiscal 2017.

*Defined contribution plans*

The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Plan, to which both the Company and participating employees contribute. The Company’s contribution is in the form of a guaranteed match which is approved annually by the Walgreen Co. Board of Directors and reviewed by the Compensation Committee and Finance Committee of the Walgreens Boots Alliance Board of Directors. The profit-sharing provision was an expense of \$58 million and \$164 million for the three and nine months ended May 31, 2017 compared to an expense of \$58 million and \$169 million in the three and nine months ended May 31, 2016.

The Company also has other contract based as well as statutory defined contribution schemes, including the Alliance Healthcare & Boots Retirement Savings Plan, to which both the Company and participating employees contribute. The cost recognized in the Consolidated Condensed Statements of Earnings for the three and nine months ended May 31, 2017 was \$26 million and \$82 million compared to a cost of \$33 million and \$102 million in the three and nine months ended May 31, 2016.

*Postretirement Healthcare Plan*

The Company provides certain health insurance benefits to retired U.S. employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the service life of the employee. An amendment to this plan in the third quarter of fiscal 2017 resulted in a \$109 million curtailment gain.

**Note 12. Earnings per share**

The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 6.4 million outstanding options to purchase common shares that were anti-dilutive and excluded from the third quarter earnings per share calculation as of May 31, 2017 compared to 2.8 million as of May 31, 2016. Anti-dilutive shares excluded from the year to date earnings per share calculation were 5.7 million compared to 2.4 million for the periods ended May 31, 2017 and May 31, 2016, respectively.

**Note 13. Depreciation and amortization**

The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):

	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Depreciation expense	\$ 334	\$ 353	\$ 1,000	\$ 997
Intangible asset and other amortization	79	94	244	274
Total depreciation and amortization expense	\$ 413	\$ 447	\$ 1,244	\$ 1,271

**Note 14. Supplemental information**

The effective tax rate for the three months ended May 31, 2017 was 12.4% compared to 22.8% for the prior year period. The effective tax rate for the nine months ended May 31, 2017 was 16.2% compared to 20.2% for the prior year period. The decrease in the effective tax rate for the three months and nine months ended May 31, 2017 was primarily attributable to net incremental discrete tax benefits and a lower estimated annual tax rate. Cash paid for income taxes was \$839 million and \$812 million in the nine months ended May 31, 2017 and May 31, 2016, respectively.

Interest paid was \$573 million and \$512 million for the nine months ended May 31, 2017 and May 31, 2016, respectively.

**Note 15. Accumulated other comprehensive income (loss)**

The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and nine months ended May 31, 2017 and May 31, 2016 (in millions):

	Pension/ post-retirement obligations	Unrecognized gain (loss) on available-for-sale investments	Unrealized gain (loss) on cash flow hedges	Share of OCI of equity method investments	Currency translation adjustment	Total
Balance at February 28, 2017	\$ (216)	\$ 1	\$ (35)	\$ (6)	\$ (3,553)	\$ (3,809)
Other comprehensive income (loss) before reclassification adjustments	(102)	(1)	—	4	499	400
Amounts reclassified from accumulated OCI <sup>1</sup>	109	—	1	—	—	110
Tax benefit (provision)	(2)	—	—	(2)	—	(4)
Net other comprehensive income (loss)	5	(1)	1	2	499	506
Balance at May 31, 2017	\$ (211)	\$ —	\$ (34)	\$ (4)	\$ (3,054)	\$ (3,303)
	Pension/ post-retirement obligations	Unrecognized gain (loss) on available-for-sale investments	Unrealized gain (loss) on cash flow hedges	Share of OCI of equity method investments	Currency translation adjustment	Total
Balance at August 31, 2016	\$ (212)	\$ 2	\$ (37)	\$ (1)	\$ (2,744)	\$ (2,992)
Other comprehensive income (loss) before reclassification adjustments	(107)	(2)	—	(4)	(310)	(423)
Amounts reclassified from accumulated OCI <sup>1</sup>	109	—	4	—	—	113
Tax benefit (provision)	(1)	—	(1)	1	—	(1)
Net other comprehensive income (loss)	1	(2)	3	(3)	(310)	(311)
Balance at May 31, 2017	\$ (211)	\$ —	\$ (34)	\$ (4)	\$ (3,054)	\$ (3,303)



	Pension/ post-retirement obligations	Unrecognized gain (loss) on available-for-sale investments	Unrealized gain (loss) on cash flow hedges	Share of OCI of equity method investments	Currency translation adjustment	Total
Balance at February 29, 2016	\$ 30	\$ 172	\$ (38)	\$ —	\$ (2,032)	\$ (1,868)
Other comprehensive income (loss) before reclassification adjustments	5	(6)	—	—	762	761
Amounts reclassified from accumulated OCI	—	(268)	1	—	(2)	(269)
Tax benefit (provision)	(2)	102	(1)	—	—	99
Net other comprehensive income (loss)	3	(172)	—	—	760	591
Balance at May 31, 2016	\$ 33	\$ —	\$ (38)	\$ —	\$ (1,272)	\$ (1,277)

	Pension/ post-retirement obligations	Unrecognized gain (loss) on available-for-sale investments	Unrealized gain (loss) on cash flow hedges	Share of OCI of equity method investments	Currency translation adjustment	Total
Balance at August 31, 2015	\$ 29	\$ 259	\$ (40)	\$ —	\$ (462)	\$ (214)
Other comprehensive income (loss) before reclassification adjustments	4	(150)	—	—	(808)	(954)
Amounts reclassified from accumulated OCI	—	(268)	4	—	(2)	(266)
Tax benefit (provision)	—	159	(2)	—	—	157
Net other comprehensive income (loss)	4	(259)	2	—	(810)	(1,063)
Balance at May 31, 2016	\$ 33	\$ —	\$ (38)	\$ —	\$ (1,272)	\$ (1,277)

<sup>1</sup> Includes amendment to U.S. postretirement healthcare plan resulting in a curtailment gain. See note 11, Retirement benefits.

**Note 16. Segment reporting**

The Company has three reportable segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The operating segments have been identified based on the financial data utilized by the Company's Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company's operating segments, which have been aggregated as described below. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.

- The Retail Pharmacy USA segment consists of retail drugstores and convenient care clinics and the provision of central specialty and mail pharmacy services. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.
- The Retail Pharmacy International segment consists primarily of pharmacy-led health and beauty stores and optical practices. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, the Netherlands and Lithuania. Sales for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.
- The Pharmaceutical Wholesale segment consists of pharmaceutical wholesaling and distribution businesses and an equity method investment in AmerisourceBergen reported on a two-month lag. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Sales for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals,

health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.

Results for each reportable segment include the allocation of procurement rebates and corporate-related overhead costs. The “Eliminations” column includes intersegment sales and the profit on these intersegment sales to the extent the inventory has not been subsequently sold externally.

To improve comparability, certain classification changes were made to prior period sales, cost of sales and selling, general and administrative expenses. These changes had no impact on operating income or adjusted operating income. The reclassifications were made in the fourth quarter of fiscal 2016.

The following table reflects results of operations of the Company’s reportable segments (in millions):

	<b>Retail Pharmacy USA</b>	<b>Retail Pharmacy International</b>	<b>Pharmaceutical Wholesale</b>	<b>Eliminations</b>	<b>Walgreens Boots Alliance, Inc.</b>
<b>Three months ended May 31, 2017</b>					
Sales to external customers	\$ 22,528	\$ 2,809	\$ 4,781	\$ —	\$ 30,118
Intersegment sales	—	—	515	(515)	—
Sales	<u>\$ 22,528</u>	<u>\$ 2,809</u>	<u>\$ 5,296</u>	<u>\$ (515)</u>	<u>\$ 30,118</u>
Adjusted operating income	<u>\$ 1,463</u>	<u>\$ 193</u>	<u>\$ 253</u>	<u>\$ 5</u>	<u>\$ 1,914</u>
<b>Three months ended May 31, 2016</b>					
Sales to external customers	\$ 21,185	\$ 3,132	\$ 5,181	\$ —	\$ 29,498
Intersegment sales	—	—	567	(567)	—
Sales	<u>\$ 21,185</u>	<u>\$ 3,132</u>	<u>\$ 5,748</u>	<u>\$ (567)</u>	<u>\$ 29,498</u>
Adjusted operating income	<u>\$ 1,382</u>	<u>\$ 258</u>	<u>\$ 179</u>	<u>\$ (5)</u>	<u>\$ 1,814</u>
<b>Nine months ended May 31, 2017</b>					
Sales to external customers	\$ 65,001	\$ 8,872	\$ 14,192	\$ —	\$ 88,065
Intersegment sales	—	—	1,551	(1,551)	—
Sales	<u>\$ 65,001</u>	<u>\$ 8,872</u>	<u>\$ 15,743</u>	<u>\$ (1,551)</u>	<u>\$ 88,065</u>
Adjusted operating income	<u>\$ 4,304</u>	<u>\$ 648</u>	<u>\$ 703</u>	<u>\$ 1</u>	<u>\$ 5,656</u>
<b>Nine months ended May 31, 2016</b>					
Sales to external customers	\$ 63,055	\$ 10,219	\$ 15,441	\$ —	\$ 88,715
Intersegment sales	—	—	1,730	(1,730)	—
Sales	<u>\$ 63,055</u>	<u>\$ 10,219</u>	<u>\$ 17,171</u>	<u>\$ (1,730)</u>	<u>\$ 88,715</u>
Adjusted operating income	<u>\$ 4,257</u>	<u>\$ 908</u>	<u>\$ 500</u>	<u>\$ (12)</u>	<u>\$ 5,653</u>

The following table reconciles adjusted operating income to operating income (in millions):

	<b>Retail Pharmacy USA</b>	<b>Retail Pharmacy International</b>	<b>Pharmaceutical Wholesale</b>	<b>Eliminations</b>	<b>Walgreens Boots Alliance, Inc.</b>
<b>Three months ended May 31, 2017</b>					
Adjusted operating income	\$ 1,463	\$ 193	\$ 253	\$ 5	\$ 1,914
Cost transformation					(171)
Acquisition-related amortization					(83)
LIFO provision					(97)
Adjustments to equity earnings in AmerisourceBergen					(17)
Acquisition-related costs					(29)
Operating income					<u>\$ 1,517</u>
<b>Three months ended May 31, 2016</b>					
Adjusted operating income	\$ 1,382	\$ 258	\$ 179	\$ (5)	\$ 1,814
Cost transformation					(73)
Acquisition-related amortization					(96)
LIFO provision					(92)
Adjustments to equity earnings in AmerisourceBergen					(5)
Acquisition-related costs					(15)
Operating income					<u>\$ 1,533</u>
	<b>Retail Pharmacy USA</b>	<b>Retail Pharmacy International</b>	<b>Pharmaceutical Wholesale</b>	<b>Eliminations</b>	<b>Walgreens Boots Alliance, Inc.</b>
<b>Nine months ended May 31, 2017</b>					
Adjusted operating income	\$ 4,304	\$ 648	\$ 703	\$ 1	\$ 5,656
Cost transformation					(592)
Acquisition-related amortization					(247)
LIFO provision					(204)
Adjustments to equity earnings in AmerisourceBergen					(95)
Acquisition-related costs					(75)
Operating income					<u>\$ 4,443</u>
<b>Nine months ended May 31, 2016</b>					
Adjusted operating income	\$ 4,257	\$ 908	\$ 500	\$ (12)	\$ 5,653
Cost transformation					(191)
Acquisition-related amortization					(278)
LIFO provision					(206)
Adjustments to equity earnings in AmerisourceBergen					(5)
Acquisition-related costs					(82)
Asset impairment					(30)
Operating income					<u>\$ 4,861</u>

**Note 17. New accounting pronouncements**

**Adoption of new accounting pronouncements**

*Modifications of share-based payments*

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. This ASU is effective for fiscal years beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years. The Company early adopted this guidance on a prospective basis during the quarter ended May 31, 2017. The adoption did not have any impact on the Company’s results of operations, cash flows or financial position.

#### **New accounting pronouncements not yet adopted**

##### *Presentation of net periodic pension cost and net period postretirement benefit cost*

In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This ASU requires an employer to report the service cost component of net periodic pension cost and net periodic postretirement cost in the same line item in the statement of earnings as other compensation costs arising from services rendered by the related employees during the period. The other net cost components are required to be presented in the statement of earnings separately from the service cost component and outside a subtotal of income from operations. Additionally, the line item used in the statement of earnings to present the other net cost components must be disclosed in the notes to the financial statements. This ASU is effective for fiscal years beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years, with early adoption permitted. The new guidance must be applied on a retrospective basis. The adoption of this ASU is not expected to have a significant impact on Company’s consolidated financial statements.

##### *Restricted cash*

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. This ASU requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years, with early adoption permitted. The new guidance must be applied on a retrospective basis. The adoption of this ASU is not expected to have a significant impact on Company’s consolidated financial statements.

##### *Tax accounting for intra-entity asset transfers*

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Topic 740, Income Taxes, prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. In addition, interpretations of this guidance have developed in practice for transfers of certain intangible and tangible assets. This prohibition on recognition is an exception to the principle of comprehensive recognition of current and deferred income taxes in GAAP. To more faithfully represent the economics of intra-entity asset transfers, the amendments in this ASU require that entities recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments in this ASU do not change GAAP for the pre-tax effects of an intra-entity asset transfer under Topic 810, Consolidation, or for an intra-entity transfer of inventory. This ASU is effective for fiscal years beginning after December 15, 2017 (fiscal 2019), including interim periods within those fiscal years, with early adoption permitted. The new guidance must be applied on a modified retrospective basis through a cumulative effect adjustment recognized directly to retained earnings as of the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance.

##### *Classification of certain cash receipts and cash payments*

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This ASU addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. This ASU is effective for fiscal years beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years, with early adoption permitted. An entity that elects early adoption must adopt all of the amendments in the same period and must be applied on a retrospective basis. The Company is evaluating the effect this ASU will have on its consolidated statement of cash flows.

##### *Recognition of breakage for prepaid stored-value products*

In March 2016, the FASB issued ASU 2016-04, Liabilities-Extinguishments of Liabilities (Subtopic 405-20): Recognition of Breakage for Certain Prepaid Stored-Value Products. This ASU addresses diversity in practice related to the derecognition of a prepaid store-value product liability. The ASU amends the guidance on extinguishing financial liabilities for certain prepaid store-value products. If an entity selling prepaid store-value products expects to be entitled to an amount that will not be redeemed, the entity will recognize the expected breakage in proportion to the pattern of rights expected to be exercised by the product holder to the extent that it is probable that a significant reversal of the breakage amount will not subsequently occur. The ASU is effective for annual periods beginning after December 15, 2017 (fiscal 2019), and interim periods within those fiscal years, with early adoption permitted, including adoption before the effective date of ASU 2015-14, Revenue from Contracts with Customers (described below). The amendments in this ASU should be applied either on a modified retrospective basis through a cumulative effect adjustment recognized directly to retained earnings as of the date of adoption or retrospectively to each period presented. The Company is evaluating the effect the ASU will have on its consolidated financial statements.

#### *Leases*

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes Topic 840, Leases. This ASU increases the transparency and comparability of organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. At the lease commencement date, lessee recognizes a lease liability and right-of-use asset, which is initially measured at the present value of future lease payments. Under the finance lease approach, interest on the lease liability is recognized separately from amortization of the right-of-use asset. Repayments of the principal portion of the lease liability will be classified as financing activities and payments of interest on the lease liability and variable lease payments will be classified as operating activities in the statement of cash flows. Under the operating lease approach, the cost of the lease is calculated on a straight-line basis over the life of the lease term. All cash payments are classified as operating activities in the statement of cash flows. For sale and leaseback transactions, in order for a sale to occur, the transfer of the asset must meet all criteria in Topic 606. Any consideration paid for the asset is accounted for as a financing transaction. For transactions previously accounted for as a sale and leaseback, the transition guidance in Topic 842 does not require an entity to assess whether the transaction would have qualified as a sale and a leaseback in accordance with Topic 842. Additionally, gains recorded under sale and leaseback transactions are recognized at the transaction date and no longer deferred over the lease term. This ASU is effective for annual periods beginning after December 15, 2018 (fiscal 2020). In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented (fiscal 2018) using a modified retrospective approach which includes a number of optional practical expedients that entities may elect to apply. The Company has begun evaluating and planning for the adoption and implementation of this ASU, including assessing the overall impact. This ASU will have a material impact on the Company's financial position. The impact on the Company's results of operations is being evaluated. The impact of this ASU is non-cash in nature and will not affect the Company's cash position.

#### *Classification and measurement of financial instruments*

In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This ASU requires equity investments (except those under the equity method of accounting or those that result in the consolidation of an investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. This simplifies the impairment assessment of equity investments previously held at cost. Separate presentation of financial assets and liabilities by measurement category is required. This ASU is effective prospectively for annual periods beginning after December 15, 2017 (fiscal 2019). Early application is permitted, for fiscal years or interim periods that have not yet been issued as of the beginning of the fiscal year of adoption. The Company is evaluating the effect of adopting this new accounting guidance.

#### *Revenue recognition on contracts with customers*

In May 2015, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU removes inconsistencies, complexities and allows transparency and comparability of revenue transactions across entities, industries, jurisdictions and capital markets by providing a single comprehensive principles-based model with additional disclosures regarding uncertainties. The principles-based revenue recognition model has a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of ASU 2014-09 by one year to annual reporting periods beginning after December 15, 2017 (fiscal 2019) and is the date on which the Company expects to adopt the new guidance. Subsequently, the FASB has also issued additional accounting standards updates to clarify the guidance in ASU 2014-09, all of which must be adopted concurrently. In transition, the ASU may be applied retrospectively to each prior period

presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance.

#### *Measurement of inventory*

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. This ASU simplifies current accounting treatments by requiring entities to measure most inventories at “the lower of cost and net realizable value” rather than using lower of cost or market. This guidance does not apply to inventories measured using last-in, first-out method or the retail inventory method. This ASU is effective prospectively for annual periods beginning after December 15, 2016 and interim periods thereafter (fiscal 2018) with early adoption permitted. Upon transition, entities must disclose the accounting change. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company’s results of operations, cash flows or financial position.

#### **Note 18. Related parties**

The Company has a long-term pharmaceutical distribution agreement with AmerisourceBergen pursuant to which the Company sources branded and generic pharmaceutical products from AmerisourceBergen principally for its U.S. operations.

Related party transactions (in millions):

	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Purchases, net	\$ 10,703	\$ 10,632	\$ 31,941	\$ 31,436
			May 31, 2017	August 31, 2016
Trade accounts payable, net			\$ 4,148	\$ 3,456

Additionally, AmerisourceBergen receives sourcing services for generic pharmaceutical products.

#### **Item 2. Management’s discussion and analysis of financial condition and results of operations**

*The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes included elsewhere herein and the consolidated financial statements, accompanying notes and Management’s discussion and analysis of financial condition and results of operations and other disclosures contained in the Walgreens Boots Alliance, Inc. Annual Report on Form 10-K for the fiscal year ended August 31, 2016. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are not limited to, those discussed under “Cautionary note regarding forward-looking statements” and in Item 1A “Risk factors” in our Form 10-K for the fiscal year ended August 31, 2016 and in Item 1A “Risk factors” in this report. References herein to the “Company”, “we”, “us”, or “our” refer to Walgreens Boots Alliance, Inc. and its subsidiaries, except as otherwise indicated or the context otherwise requires.*

#### **INTRODUCTION AND SEGMENTS**

Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance”) and its subsidiaries are a global pharmacy-led health and wellbeing enterprise. Its operations are conducted through three reportable segments:

- Retail Pharmacy USA;
- Retail Pharmacy International; and
- Pharmaceutical Wholesale

See note 16, Segment reporting for further information.

On March 31, 2017, Walgreens Boots Alliance and pharmacy benefit manager Prime Therapeutics LLC closed a transaction to form a combined central specialty pharmacy and mail services company AllianceRx Walgreens Prime, as part of a strategic alliance. AllianceRx Walgreens Prime is consolidated by Walgreens Boots Alliance and reported within the Retail Pharmacy USA division in its financial statements. See note 5, Acquisitions for further information.

#### *Terminated acquisition of Rite Aid Corporation (“Rite Aid”) and related matters*

On October 27, 2015, Walgreens Boots Alliance entered into an Agreement and Plan of Merger with Rite Aid and Victoria Merger Sub, Inc., a wholly-owned subsidiary of Walgreens Boots Alliance (as amended as described below, the “Merger

Agreement”), pursuant to which the Company agreed, subject to the terms and conditions thereof, to acquire Rite Aid, a drugstore chain in the United States. The Merger Agreement was amended by Amendment No. 1 thereto on January 29, 2017.

In connection with regulatory review of the merger contemplated by the Merger Agreement, on December 20, 2016, Walgreens Boots Alliance and Rite Aid announced that they had entered into an agreement (the “Fred’s Asset Purchase Agreement”), subject to the terms and conditions thereof, to sell certain Rite Aid stores and certain assets related to store operations to Fred’s, Inc. (“Fred’s”) for \$950 million in an all-cash transaction. The transaction was subject to the approval and completion of the acquisition of Rite Aid by Walgreens Boots Alliance pursuant to the Merger Agreement.

On June 28, 2017, Walgreens Boots Alliance and Rite Aid entered into a mutual termination agreement (the “Termination Agreement”) pursuant to which the parties agreed to terminate the Merger Agreement, including all schedules and exhibits thereto, and all ancillary agreements contemplated thereby, or entered pursuant thereto (other than as expressly specified) (collectively with the Merger Agreement, the “Transaction Documents”), effective as of June 28, 2017. Pursuant to the Termination Agreement, the Company agreed to pay Rite Aid the termination fee of \$325 million, which amount the Company plans to pay on or before June 30, 2017 in full satisfaction of any amounts required to be paid by the Company under the Merger Agreement and other Transaction Documents. The parties also agreed to release each other from, among other things, any and all liability, claims, rights, actions, causes of action, damages, expenses and fees, however arising, in connection with, arising out of or related to the Transaction Documents, the transactions contemplated therein or thereby or certain related matters.

On June 28, 2017, following the termination of the Merger Agreement, the Fred’s Asset Purchase Agreement was terminated. In connection with the termination of the Fred’s Asset Purchase Agreement, the Company agreed to reimburse certain of Fred’s transaction costs in an amount not to exceed \$25 million in full satisfaction of any amounts required to be paid by the Company under the Fred’s Asset Purchase Agreement. The Company expects to pay the applicable amount during the fourth quarter of fiscal 2017.

See note 7, Borrowings and note 10, Commitments and contingencies to the consolidated condensed financial statements for additional information relating to the termination of the Merger Agreement and related matters.

#### *Pending acquisition of certain Rite Aid assets*

On June 28, 2017, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Rite Aid, pursuant to which the Company agreed, subject to the terms and conditions thereof, to acquire 2,186 stores, three distribution centers and related inventory from Rite Aid. The consideration for the transaction will be \$5.175 billion in cash, the assumption by the Company of the related real estate leases and the grant of an option to Rite Aid, exercisable through May 2019 and subject to certain conditions, to become a member of the Company’s group purchasing organization, Walgreens Boots Alliance Development GmbH. The Company will also assume certain limited store-related liabilities as part of the transaction.

The Company intends to finance the acquisition through a combination of cash on hand and funds available under existing credit facilities and arrangements. The transaction is subject to the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions. The initial closing is expected to occur within the next six months. Upon the initial closing of the transaction, the Company will begin acquiring the stores and related assets on a phased basis.

#### **AMERISOURCEBERGEN CORPORATION RELATIONSHIP**

As of May 31, 2017, the Company owned 56,854,867 AmerisourceBergen common shares representing approximately 26% of the outstanding AmerisourceBergen common stock, and had designated one member of AmerisourceBergen’s board of directors. As of May 31, 2017, the Company can acquire up to an additional 8,398,752 AmerisourceBergen shares in the open market and thereafter designate another member of AmerisourceBergen’s board of directors, subject in each case to applicable legal and contractual requirements. The amount of permitted open market purchases is subject to increase or decrease in certain circumstances.

Effective March 18, 2016, the Company accounted for the investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings attributable to the investment being classified within the operating income of the Pharmaceutical Wholesale segment. See note 4, Equity method investments, to the Consolidated Condensed Financial Statements for further information.

#### **RESTRUCTURING PROGRAMS**

On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the “Cost Transformation Program”) as part of an initiative to reduce costs and increase operating efficiencies. The Cost

Transformation Program implements and builds on the planned three-year, \$1.0 billion cost-reduction initiative previously announced by Walgreens on August 6, 2014 and includes a number of elements designed to help achieve profitable growth through increased cost efficiencies. In April 2015, the Company announced that it had identified additional opportunities for cost savings that increased the total expected cost savings of the Cost Transformation Program by \$500 million to a targeted \$1.5 billion by the end of fiscal 2017, with significant areas of focus including plans to close approximately 200 stores across the U.S.; reorganize divisional and field operations; drive operating efficiencies; and streamline information technology and other functions. The actions under the Cost Transformation Program focus primarily on the Company’s Retail Pharmacy USA segment. The Company achieved \$1.5 billion in savings from its previously announced Cost Transformation Program ahead of schedule. As previously reported, the Company expects to close a total of approximately 260 stores and the program is on track to be completed by the end of fiscal 2017. Accordingly, full program benefits will be recognized in subsequent periods.

As of the date of this report, the Company estimates that the Cost Transformation Program will recognize cumulative pre-tax charges to its financial results in accordance with generally accepted accounting principles in the United States of America (“GAAP”) of approximately \$1.8 billion (which is consistent with the upper end of the expected range of pre-tax charges at the time the Cost Transformation Program was launched in April 2015). These charges include costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. As of the date of this report, the Company expects to incur pre-tax charges of approximately \$675 million for real estate costs, including lease obligations (net of estimated sublease income); \$725 million for asset impairment charges relating primarily to asset write-offs from store closures, information technology, inventory and other non-operational real estate asset write-offs; and \$400 million for employee severance and other business transition and exit costs. The Company estimates that approximately 60% of the cumulative pre-tax charges will result in cash expenditures over time, primarily related to historical and future lease and other real estate payments and employee separation costs. See note 2. Restructuring, to the Consolidated Financial Statements for additional information.

The amounts and timing of all estimates are subject to change until finalized. The actual amounts and timing may vary materially based on various factors. See “Cautionary Note Regarding Forward-Looking Statements” below.

**EXECUTIVE SUMMARY**

The following table presents certain key financial statistics for the three and nine months ended May 31, 2017 and May 31, 2016 , respectively.

	(in millions, except per share amounts)			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Sales	\$ 30,118	\$ 29,498	\$ 88,065	\$ 88,715
Gross profit <sup>2</sup>	7,145	7,433	21,822	22,719
Selling, general and administrative expenses <sup>2</sup>	5,712	5,903	17,522	17,861
Equity earnings in AmerisourceBergen	84	3	143	3
Operating income	1,517	1,533	4,443	4,861
Adjusted operating income (Non-GAAP measure) <sup>1</sup>	1,914	1,814	5,656	5,653
Earnings before interest and income tax provision	1,509	1,561	4,421	4,336
Net earnings attributable to Walgreens Boots Alliance, Inc.	1,162	1,103	3,276	3,143
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure) <sup>1</sup>	1,441	1,288	4,118	3,843
Net earnings per common share – diluted	1.07	1.01	3.02	2.88
Adjusted net earnings per common share – diluted (Non-GAAP measure) <sup>1</sup>	1.33	1.18	3.79	3.52



	Percentage increases (decreases) from prior year			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016 <sup>3</sup>
Sales	2.1	2.4	(0.7)	18.4
Gross profit <sup>2</sup>	(3.9)	0.2	(3.9)	16.2
Selling, general and administrative expenses <sup>2</sup>	(3.2)	(1.9)	(1.9)	11.3
Operating income	(1.0)	9.4	(8.6)	26.9
Adjusted operating income (Non-GAAP measure) <sup>1</sup>	5.5	3.7	0.1	20.1
Earnings before interest and income tax provision	(3.3)	(16.2)	2.0	(24.0)
Net earnings attributable to Walgreens Boots Alliance, Inc.	5.3	(15.3)	4.2	(25.1)
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure) <sup>1</sup>	11.9	14.7	7.2	23.3
Net earnings per common share – diluted	5.9	(14.4)	4.9	(28.7)
Adjusted net earnings per common share – diluted (Non-GAAP measure) <sup>1</sup>	12.7	15.7	7.7	17.3
	Percent to sales			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Gross margin <sup>2</sup>	23.7	25.2	24.8	25.6
Selling, general and administrative expenses <sup>2</sup>	19.0	20.0	19.9	20.1

- <sup>1</sup> See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with generally accepted accounting principles in the United States (“GAAP”).
- <sup>2</sup> To improve comparability, certain classification changes were made to prior period sales, cost of sales and selling, general and administrative expenses. These changes had no impact on operating income or adjusted operating income. The reclassifications were made in the fourth quarter of fiscal 2016.
- <sup>3</sup> The nine months ended May 31, 2016 include the results of Alliance Boots GmbH on a fully consolidated basis, while the nine months ended May 31, 2015 include the results of Alliance Boots GmbH for five months on a fully consolidated basis and for four months as equity earnings in Alliance Boots GmbH reflecting Walgreen Co.'s pre-merger 45% interest.

**WALGREENS BOOTS ALLIANCE RESULTS OF OPERATIONS**

Net earnings attributable to Walgreens Boots Alliance for the three months ended May 31, 2017 increased 5.3% to \$1,162 million compared with the prior year period, while diluted net earnings per share increased 5.9% to \$1.07 compared with the prior year period. The increases in net earnings and diluted net earnings per share for the three month period ended May 31, 2017 primarily reflect a lower effective tax rate. Net earnings and diluted net earnings per share were negatively impacted by 1.5 percentage points and 2.0 percentage points, respectively, as a result of currency translation.

Net earnings attributable to Walgreens Boots Alliance for the nine months ended May 31, 2017 increased 4.2% to \$3.3 billion compared with the prior year period, while diluted net earnings per share increased 4.9% to \$3.02 compared with the prior year period. The increases in net earnings and diluted net earnings per share for the nine month period ended May 31, 2017 primarily reflect the reduction in the fair value of the Company’s AmerisourceBergen warrants in the year-ago period partially offset by higher costs related to the Cost Transformation Program in the current period. Net earnings and diluted net earnings per share were each negatively impacted by 2.4 percentage points as a result of currency translation.

Other income (expense) for the three and nine months ended May 31, 2017 was an expense of \$8 million and \$22 million, respectively, as compared to an income of \$28 million and an expense of \$525 million, respectively, in the three and nine months ended May 31, 2016. The comparable periods included expenses of \$259 million and \$845 million for the reduction in the fair value of the AmerisourceBergen warrants for the three and nine months ended May 31, 2016, respectively, and \$268 million income in both periods for the change in accounting method for the Company's investment in AmerisourceBergen.

[Table of Contents](#)

Interest was a net expense of \$155 million and \$500 million for the three and nine months ended May 31, 2017, respectively, compared to \$147 million and \$425 million in the three and nine months ended May 31, 2016, respectively. The increases mainly reflect the interest expense associated with the debt financing for the then-pending acquisition of Rite Aid.

The effective tax rate for the three months ended May 31, 2017 was 12.4% compared to 22.8% for the prior year period. The effective tax rate for the nine months ended May 31, 2017 was 16.2% compared to 20.2% for the prior year period. The decrease in the effective tax rate for the three months and nine months ended May 31, 2017 was primarily attributable to net incremental discrete tax benefits and a lower estimated annual tax rate. The lower estimated annual tax rate was mostly a result of forecast changes in the geographic mix of our pre-tax earnings, increased benefits associated with the U.S. taxation of our non-U.S. operations and additional favorable permanent book-tax differences, including tax credits. For the three months ended May 31, 2017 discrete tax benefits resulted primarily from net tax benefits associated with prior tax years. For the nine months ended May 31, 2017 discrete tax benefits resulted primarily from adopting ASU 2016-09 and net tax benefits associated with prior tax years.

Walgreens Boots Alliance adjusted diluted net earnings per share (Non-GAAP measure)

Adjusted net earnings attributable to Walgreens Boots Alliance for the three months ended May 31, 2017 increased 11.9% to \$1.4 billion, compared with the year-ago quarter. Adjusted diluted net earnings per share increased 12.7% to \$1.33, compared with the year-ago quarter. Adjusted net earnings and adjusted diluted net earnings per share were each negatively impacted by 1.7 percentage points as a result of currency translation.

Excluding the impact of currency translation, the increase in adjusted net earnings and adjusted diluted net earnings per share for the three months ended May 31, 2017 was primarily due to an increase in equity earnings from AmerisourceBergen and a lower effective tax rate.

Adjusted net earnings attributable to Walgreens Boots Alliance for the nine months ended May 31, 2017, increased 7.2% to \$4.1 billion, compared with the year-ago period. Adjusted diluted net earnings per share increased 7.7% to \$3.79, compared with the year-ago period. Adjusted net earnings and adjusted diluted net earnings per share were negatively impacted by 2.1 percentage points and 2.2 percentage points, respectively, as a result of currency translation.

Excluding the impact of currency translation, the increase in adjusted net earnings and adjusted diluted net earnings per share for the nine months ended May 31, 2017 was primarily due to an increase in equity earnings from AmerisourceBergen and a lower effective tax rate. See "--Non-GAAP Measures" below for a reconciliation to the most directly comparable GAAP measure.

## **RESULTS OF OPERATIONS BY SEGMENT**

### ***Retail Pharmacy USA***

	(in millions, except location amounts)			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Sales	\$ 22,528	\$ 21,185	\$ 65,001	\$ 63,055
Gross profit	5,507	5,603	16,822	16,943
Selling, general and administrative expenses	4,337	4,434	13,427	13,317
Operating income	1,170	1,169	3,395	3,626
Adjusted operating income (Non-GAAP measure) <sup>1</sup>	1,463	1,382	4,304	4,257
Number of prescriptions <sup>2</sup>	196.0	187.4	575.8	560.0
30-day equivalent prescriptions <sup>2,3</sup>	255.2	235.3	739.5	699.0
Number of locations at period end	8,138	8,208	8,138	8,208

	Percentage increases (decreases) from prior year			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Sales	6.3	3.7	3.1	3.3
Gross profit	(1.7)	1.4	(0.7)	2.3
Selling, general and administrative expenses	(2.2)	(1.3)	0.8	(1.4)
Operating income	0.1	13.2	(6.4)	7.3
Adjusted operating income (Non-GAAP measure) <sup>1</sup>	5.9	4.1	1.1	5.3
Comparable store sales <sup>4,5</sup>	3.7	3.9	2.6	3.9
Pharmacy sales	10.3	5.8	5.5	5.2
Comparable pharmacy sales <sup>4,5</sup>	5.8	6.0	4.4	6.3
Retail sales	(1.8)	(0.4)	(1.9)	(0.3)
Comparable retail sales <sup>4</sup>	(0.4)	0.1	(0.6)	(0.2)
Comparable number of prescriptions <sup>2,4</sup>	4.8	2.8	3.6	2.5
Comparable 30-day equivalent prescriptions <sup>2,3,4</sup>	8.3	4.5	6.5	4.0

	Percent to sales			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Gross margin	24.4	26.4	25.9	26.9
Selling, general and administrative expenses	19.3	20.9	20.7	21.1

<sup>1</sup> See "--Non-GAAP Measures" below for a reconciliation to the most directly comparable GAAP measure and related disclosures.

<sup>2</sup> Includes immunizations.

<sup>3</sup> Includes the adjustment to convert prescriptions greater than 84 days to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.

<sup>4</sup> Comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or subject to a natural disaster in the past twelve months. Relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. The method of calculating comparable sales varies across the industries in which we operate. As a result, our method of calculating comparable sales may not be the same as other companies' methods. The nine month period ended May 31, 2016 comparable sales and comparable prescription figures include an adjustment to remove February 29, 2016 results due to the leap year.

<sup>5</sup> Comparable store sales and comparable pharmacy sales for the three and six months ended February 28, 2017 reflect certain revisions. These revisions did not impact the Company's financial statements and resulted in increases to previously reported comparable store sales and comparable pharmacy sales from 2.4% and 4.2%, respectively, to 3.1% and 5.3%, respectively, for the three months ended February 28, 2017 and from 1.8% and 3.0%, respectively, to 2.1% and 3.6%, respectively, for the six months ended February 28, 2017.

Sales for the three months ended May 31, 2017 and May 31, 2016

Retail Pharmacy USA division's sales for the three months ended May 31, 2017 increase d by 6.3% to \$22.5 billion , which includes two months of results for AllianceRx Walgreens Prime, our recently formed central specialty and mail services business. Sales in comparable stores increase d 3.7% compared with the year-ago quarter.

Pharmacy sales increase d by 10.3% for the three months ended May 31, 2017 and represented 69.9% of the division's sales. Sales include two months of AllianceRx Walgreens Prime. The increase in the current quarter is mainly due to higher prescription volumes including central specialty and mail following the formation of AllianceRx Walgreens Prime. In the year-ago quarter, pharmacy sales increased 5.8% and represented 67.4% of the division's sales. Comparable pharmacy sales increase d 5.8% for the three months ended May 31, 2017 , compared to an increase of 6.0% in the year-ago quarter, primarily due to strong volume growth from Medicare Part D and volume growth from previously announced strategic pharmacy partnerships. The effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription

sales by 2.6% in the three months ended May 31, 2017 compared to a reduction of 1.8% in the year-ago quarter. On division sales, this effect was a reduction of 1.6% for the three months ended May 31, 2017 compared to a reduction of 1.1% for the year-ago quarter. The total number of prescriptions (including immunizations) filled for the three months ended May 31, 2017 was 196.0 million compared to 187.4 million in the year-ago quarter. Prescriptions (including immunizations) filled adjusted to 30-day equivalents were 255.2 million in the three months ended May 31, 2017 compared to 235.3 million in the year-ago quarter.

Retail sales decreased 1.8% for the three months ended May 31, 2017 and were 30.1% of the division's sales. In the year-ago quarter, retail sales decreased 0.4% and represented 32.6% of the division's sales. The decrease in the current quarter reflects the impact of the previously announced closure of certain e-commerce operations. Comparable retail sales decreased 0.4% in the three months ended May 31, 2017 compared to an increase of 0.1% in the year-ago quarter. The decrease in comparable retail sales growth in the current period was due to declines in the consumables and general merchandise category and in the personal care category, partially offset by growth in the health and wellness category and in the beauty category.

Operating income for the three months ended May 31, 2017 and May 31, 2016

Retail Pharmacy USA division's operating income for the three months ended May 31, 2017 increased 0.1% to \$1.2 billion. The increase was primarily due to lower expenses, partially offset by lower gross profit.

Gross profit decreased 1.7% from the year-ago quarter, reflecting a decrease in both pharmacy and retail gross profit, the latter partially related to one-time expenses associated with the Cost Transformation Program.

Selling, general and administrative expenses as a percentage of sales were 19.3% in the three months ended May 31, 2017 compared to 20.9% in the year-ago quarter. Expenses as a percentage of sales were lower in the current period primarily due to sales mix and higher sales. The Company also benefited from a reduction in expenses due to an amendment to certain employee post-retirement benefits and from the Cost Transformation Program.

Adjusted operating income (Non-GAAP measure) for the three months ended May 31, 2017 and May 31, 2016

Retail Pharmacy USA division's adjusted operating income for the three months ended May 31, 2017 increased 5.9% to \$1.5 billion. The increase was primarily due to lower expenses, partially offset by a decline in gross profit. See "--Non-GAAP Measures" below for a reconciliation to the most directly comparable GAAP measure.

Sales for the nine months ended May 31, 2017 and May 31, 2016

Retail Pharmacy USA division's total sales for the nine months ended May 31, 2017 increased 3.1% to \$65.0 billion. Sales in comparable stores increased 2.6% compared with the year-ago period.

Pharmacy sales increased by 5.5% for the nine months ended May 31, 2017 and represented 68.5% of the division's sales. In the nine months ended May 31, 2016, pharmacy sales were up 5.2% and represented 66.9% of the division's sales. Comparable pharmacy sales were up 4.4% in the nine months ended May 31, 2017 compared to an increase of 6.3% in the nine months ended May 31, 2016. The effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription sales by 2.6% in the current nine month period ended May 31, 2017 compared to a reduction of 2.1% in the year-ago period. The effect of generics on division sales was a reduction of 1.6% in the current nine month period compared to a reduction of 1.2% in the year-ago period. Third party sales, where reimbursement is received from managed care organizations, governmental agencies, employers or private insurers, were 97.7% of prescription sales for the nine month period ended May 31, 2017 compared to 97.3% for the nine months ended May 31, 2016. The total number of prescriptions (including immunizations) filled for the nine months ended May 31, 2017 was 575.8 million compared to 560.0 million for the year-ago period. Prescriptions (including immunizations) filled adjusted to 30-day equivalents were 739.5 million in the nine months ended May 31, 2017 compared to 699.0 million in the year-ago period.

Retail sales decreased 1.9% for the nine months ended May 31, 2017 and were 31.5% of the division's sales. In comparison, for the nine months ended May 31, 2016 retail sales decreased 0.3% and represented 33.1% of the division's sales. The decrease in the current period reflects the impact of the previously announced closure of certain e-commerce operations. Comparable retail sales decreased 0.6% for the current nine month period compared to a decrease of 0.2% in the year-ago period. The decrease in comparable retail sales in the nine months ended May 31, 2017 was primarily due to declines in the consumables and general merchandise category and in the personal care category, partially offset by growth in the health and wellness category and in the beauty category.

Operating income for the nine months ended May 31, 2017 and May 31, 2016

[Table of Contents](#)

Retail Pharmacy USA division's operating income for the nine months ended May 31, 2017 decreased 6.4% to \$3.4 billion. The decrease was primarily due to higher costs associated with the Cost Transformation Program, partially offset by other cost benefits.

Gross profit decreased 0.7% from the year-ago period due to a decrease in both pharmacy and retail gross profit, the latter partially related to one-time expenses associated with the Cost Transformation Program.

Selling, general and administrative expenses as a percentage of sales were 20.7% for the nine month period ended May 31, 2017 compared to 21.1% in the year-ago period. Expenses as a percentage of sales were lower in the current period primarily due to higher sales and sales mix.

***Adjusted operating income (Non-GAAP measure) for the nine months ended May 31, 2017 and May 31, 2016***

Retail Pharmacy USA division's adjusted operating income for the nine months ended May 31, 2017 increased 1.1% to \$4.3 billion. The increase was primarily due to lower selling, general and administrative expenses, partially offset by lower gross profit. See "--Non-GAAP Measures" below for a reconciliation to the most directly comparable GAAP measure.

***Retail Pharmacy International***

This division comprises businesses operating in currencies other than the U.S. dollar, including the British Pound, Euro, Chilean Peso and Mexican Peso, and therefore the division's results are impacted by movements in foreign currency exchange rates. See Item 3. Quantitative and qualitative disclosure about market risk, Foreign currency exchange rate risk for further information on currency risk.

	(in millions, except location amounts)			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Sales <sup>4</sup>	\$ 2,809	\$ 3,132	\$ 8,872	\$ 10,219
Gross profit <sup>4</sup>	1,148	1,298	3,527	4,159
Selling, general and administrative expenses <sup>4</sup>	1,006	1,075	3,005	3,335
Operating income	142	223	522	824
Adjusted operating income (Non-GAAP measure) <sup>1</sup>	193	258	648	908
Number of locations at period end	4,710	4,628	4,710	4,628

	Percentage increases (decreases) from prior year			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Sales <sup>4</sup>	(10.3)	(3.1)	(13.2)	NA
Gross profit <sup>4</sup>	(11.6)	(2.6)	(15.2)	NA
Selling, general and administrative expenses <sup>4</sup>	(6.4)	(4.6)	(9.9)	NA
Operating income	(36.3)	8.8	(36.7)	NA
Adjusted operating income (Non-GAAP measure) <sup>1</sup>	(25.2)	3.6	(28.6)	NA
Comparable store sales <sup>2</sup>	(9.9)	(5.4)	(12.9)	NA
Comparable store sales in constant currency <sup>2,3</sup>	0.2	0.2	(0.3)	NA
Pharmacy sales <sup>4</sup>	(9.7)	(3.6)	(13.2)	NA
Comparable pharmacy sales <sup>2</sup>	(9.9)	(6.6)	(13.3)	NA
Comparable pharmacy sales in constant currency <sup>2,3</sup>	(0.1)	(0.7)	(1.4)	NA
Retail sales <sup>4</sup>	(10.7)	(2.0)	(13.2)	NA
Comparable retail sales <sup>2</sup>	(10.0)	(4.6)	(12.7)	NA
Comparable retail sales in constant currency <sup>2,3</sup>	0.4	0.7	0.4	NA

	Percent to sales			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Gross margin <sup>4</sup>	40.9	41.4	39.8	40.7
Selling, general and administrative expenses <sup>4</sup>	35.8	34.3	33.9	32.6

NA Not applicable

<sup>1</sup> See "--Non-GAAP Measures" below for reconciliations to the most directly comparable GAAP measure and related disclosures.

<sup>2</sup> Comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or a natural disaster in the past twelve months. Relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. The method of calculating comparable sales varies across the industries in which we operate. As a result, our method of calculating comparable sales may not be the same as other companies' methods. The nine month period ended May 31, 2016 comparable sales figures include an adjustment to remove February 29, 2016 results due to the leap year.

<sup>3</sup> The Company presents certain information related to current period operating results in "constant currency," which is a non-GAAP financial measure. These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year. The Company presents such constant currency financial information because it has significant operations outside of the United States reporting in currencies other than the U.S. dollar and this presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. See "--Non-GAAP Measures" below.

<sup>4</sup> To improve comparability, certain classification changes were made to prior period sales, cost of sales and selling, general and administrative expenses. These changes had no impact on operating income or adjusted operating income. The reclassifications were made in the fourth quarter of fiscal 2016.

Sales for the three months ended May 31, 2017 and May 31, 2016

Retail Pharmacy International division's sales for the three months ended May 31, 2017 decrease d 10.3% to \$2.8 billion . Sales in comparable stores decrease d 9.9% from the year-ago quarter. The negative impact of currency translation on both sales and comparable sales was 10.1 percentage points and 10.1 percentage points, respectively. Comparable store sales in constant currency increase d 0.2% from the year-ago quarter.

Pharmacy sales decrease d 9.7% in the three months ended May 31, 2017 and represented 37.1% of the division's sales. Comparable pharmacy sales decrease d 9.9% from the year-ago quarter. The negative impact of currency translation on pharmacy sales and comparable pharmacy sales was 9.9 percentage points and 9.8 percentage points, respectively. Comparable pharmacy sales in constant currency decrease d 0.1% from the year-ago quarter. The decrease was mainly due to the negative impact of a reduction in pharmacy funding in the United Kingdom.

Retail sales decrease d 10.7% for the three months ended May 31, 2017 and were 62.9% of the division's sales. Comparable retail sales decrease d 10.0% from the year-ago quarter. The negative impact of currency translation on retail sales and comparable retail sales was 10.3 percentage points and 10.4 percentage points, respectively. Comparable retail sales in constant currency increase d 0.4% from the year-ago quarter reflecting growth in the United Kingdom.

Operating income for the three months ended May 31, 2017 and May 31, 2016

Retail Pharmacy International division's operating income for the three months ended May 31, 2017 decrease d 36.3% to \$142 million of which 10.7 percentage points ( \$24 million ) was as a result of the negative impact of currency translation. The remaining decrease was due to higher selling, general and administrative expenses as a percentage of sales and lower gross profit.

Gross profit decrease d 11.6% from the year-ago quarter of which 10.4 percentage points ( \$135 million ) was as a result of the negative impact of currency translation.

Selling, general and administrative expenses decrease d 6.4% from the year-ago quarter. Expenses were positively impacted by 10.3 percentage points ( \$111 million ) as a result of currency translation. As a percentage of sales, selling, general and administrative expenses were 35.8% in the current quarter, compared to 34.3% in the year-ago quarter.

Adjusted operating income (Non-GAAP measure) for the three months ended May 31, 2017 and May 31, 2016

[Table of Contents](#)

Retail Pharmacy International division's adjusted operating income for the three months ended May 31, 2017 decreased 25.2% to \$193 million of which 11.2 percentage points ( \$29 million ) was as a result of the negative impact of currency translation. The remaining decrease was primarily due to higher selling, general and administrative expenses as a percentage of sales and lower gross profit. See "--Non-GAAP Measures" below for a reconciliation to the most directly comparable GAAP measure.

Sales for the nine months ended May 31, 2017 and May 31, 2016

Retail Pharmacy International division's sales for the nine months ended May 31, 2017 decreased 13.2% to \$8.9 billion . Sales in comparable stores decreased 12.9% from the year-ago period. Of the decreases in sales and comparable store sales, 12.6 percentage points and 12.6 percentage points, respectively, were as a result of the negative impact of currency translation. Comparable store sales in constant currency decreased 0.3% from the year-ago period.

Pharmacy sales decreased by 13.2% in the nine months ended May 31, 2017 and represented 34.9% of the division's sales. Comparable pharmacy sales decreased 13.3% from the year-ago period. Of the decreases in pharmacy sales and comparable pharmacy sales, 12.0 percentage points and 11.9 percentage points, respectively, were as a result of the negative impact of currency translation. Comparable pharmacy sales in constant currency decreased 1.4% from the year-ago period. The decrease was mainly due to the negative impact of a reduction in pharmacy funding in the United Kingdom.

Retail sales decreased 13.2% for the nine months ended May 31, 2017 and were 65.1% of the division's sales. Comparable retail sales decreased 12.7% from the year-ago period.

Retail sales and comparable retail sales were negatively impacted by 13.0 percentage points and 13.1 percentage points, respectively, as a result of currency translation. Comparable retail sales in constant currency increased 0.4% from the year-ago period reflecting growth in the United Kingdom.

Operating income for the nine months ended May 31, 2017 and May 31, 2016

Retail Pharmacy International division's operating income for the nine months ended May 31, 2017 decreased 36.7% to \$522 million of which 10.0 percentage points ( \$82 million ) was as a result of the negative impact of currency translation. The remaining decrease was due to higher selling, general and administrative expenses as a percentage of sales and lower gross profit.

Gross profit decreased 15.2% from the year-ago period of which 12.5 percentage points ( \$521 million ) was as a result of the negative impact of currency translation. The remaining decrease was primarily due to lower gross profit in the United Kingdom which was impacted by reduced pharmacy funding compared to the year-ago period.

Selling, general and administrative expenses decreased 9.9% from the year-ago period. Expenses were positively impacted by 13.2 percentage points ( \$439 million ) as a result of currency translation. This was offset in part by higher depreciation over the year-ago period. As a percentage of sales, selling, general and administrative expenses were 33.9% in the current period, compared to 32.6% in the year-ago period.

Adjusted operating income (Non-GAAP measure) for the nine months ended May 31, 2017 and May 31, 2016

Retail Pharmacy International division's adjusted operating income for the nine months ended May 31, 2017 decreased 28.6% to \$648 million of which 11.0 percentage points ( \$100 million ) was as a result of the negative impact of currency translation. The remaining decrease was due to lower gross profit and higher selling, general and administrative expenses as a percentage of sales. See "--Non-GAAP Measures" below for a reconciliation to the most directly comparable GAAP measure.

**Pharmaceutical Wholesale**

This division comprises businesses operating in currencies other than the U.S. dollar including the British Pound, Euro, and Turkish Lira, and thus the division's results are impacted by movements in foreign currency exchange rates. See Item 3. Quantitative and qualitative disclosure about market risk, Foreign currency exchange rate risk for further information on currency risk.

(in millions, except location amounts)

	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
	Sales	\$ 5,296	\$ 5,748	\$ 15,743
Gross profit	491	537	1,478	1,629
Selling, general and administrative expenses	375	394	1,096	1,209
Equity earnings in AmerisourceBergen	84	3	143	3
Operating income	200	146	525	423
Adjusted operating income (Non-GAAP measure) <sup>1</sup>	253	179	703	500

Percentage increases (decreases) from prior year

	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
	Sales	(7.9)	0.7	(8.3)
Gross profit	(8.6)	(4.1)	(9.3)	NA
Selling, general and administrative expenses	(4.8)	(1.0)	(9.3)	NA
Operating income	37.0	(9.9)	24.1	NA
Adjusted operating income (Non-GAAP measure) <sup>1</sup>	41.3	4.7	40.6	NA
Comparable sales <sup>2</sup>	(7.0)	4.6	(5.4)	NA
Comparable sales in constant currency <sup>2,3</sup>	3.7	6.3	4.5	NA

Percent to sales

	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
	Gross margin	9.3	9.3	9.4
Selling, general and administrative expenses	7.1	6.9	7.0	7.0

NA Not applicable

<sup>1</sup> See "--Non-GAAP Measures" below for reconciliations to the most directly comparable GAAP measure and related disclosures.

<sup>2</sup> Comparable sales are defined as sales excluding acquisitions and dispositions. The nine month period ended May 31, 2016 comparable sales figures include an adjustment to remove February 29, 2016 results due to the leap year.

<sup>3</sup> The Company presents certain information related to current period operating results in "constant currency," which is a non-GAAP financial measure. These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year. The Company presents such constant currency financial information because it has significant operations outside of the United States reporting in currencies other than the U.S. dollar and this presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. See "--Non-GAAP Measures" below.

Sales for the three months ended May 31, 2017 and May 31, 2016

Pharmaceutical Wholesale division's sales for the three months ended May 31, 2017 decrease d 7.9% to \$5.3 billion . Comparable sales, which exclude acquisitions and dispositions, decrease d 7.0% .

Sales and comparable sales were negatively impacted by 10.6 percentage points and 10.7 percentage points, respectively, as a result of currency translation. Comparable sales in constant currency increase d 3.7% , reflecting growth in emerging markets and the United Kingdom partially offset by challenging market conditions in continental Europe.

Operating income for the three months ended May 31, 2017 and May 31, 2016

Pharmaceutical Wholesale division's operating income for the three months ended May 31, 2017 , which included \$84 million from the Company's share of equity earnings in AmerisourceBergen, increase d 37.0% to \$200 million . Operating income was negatively impacted by 11.6 percentage points ( \$17 million ) as a result of currency translation.



[Table of Contents](#)

Gross profit decrease d 8.6% from the year-ago quarter. Gross profit was negatively impacted by 10.5 percentage points ( \$56 million ) as a result of currency translation.

Selling, general and administrative expenses decrease d 4.8% from the year-ago quarter. Expenses were positively impacted by 9.9 percentage points ( \$39 million ) as a result of currency translation. As a percentage of sales, selling, general and administrative expenses were 7.1% in the current quarter, compared to 6.9% in the year-ago quarter.

Adjusted operating income (Non-GAAP measure) for the three months ended May 31, 2017 and May 31, 2016

Pharmaceutical Wholesale division's adjusted operating income for the three months ended May 31, 2017 , which included \$101 million from the Company's share of adjusted equity earnings in AmerisourceBergen, increase d 41.3% to \$253 million . Adjusted operating income was negatively impacted by 11.8 percentage points ( \$21 million ) as a result of currency translation.

Excluding the contribution from the Company's share of adjusted equity earnings in AmerisourceBergen and the negative impact of currency translation, adjusted operating income increase d 0.6% over the year-ago quarter. See "--Non-GAAP Measures" below for a reconciliation to the most directly comparable GAAP measure.

Sales for the nine months ended May 31, 2017 and May 31, 2016

Pharmaceutical Wholesale division's sales for the nine months ended May 31, 2017 decrease d 8.3% to \$15.7 billion . Comparable sales decrease d 5.4% .

Sales and comparable sales were negatively impacted by 9.6 percentage points and 9.9 percentage points respectively, as a result of currency translation. Comparable sales in constant currency increase d 4.5% , reflecting growth in emerging markets and the United Kingdom partially offset by challenging market conditions in continental Europe.

Operating income for the nine months ended May 31, 2017 and May 31, 2016

Pharmaceutical Wholesale division's operating income for the nine months ended May 31, 2017 , which included \$143 million from the Company's share of equity earnings in AmerisourceBergen, increase d 24.1% to \$525 million . Operating income was negatively impacted by 11.6 percentage points ( \$49 million ) as a result of currency translation.

Gross profit decrease d 9.3% from the year-ago period. The negative impact of currency translation was 9.7 percentage points ( \$157 million ) .

Selling, general and administrative expenses decrease d 9.3% from the year-ago period of which 8.9 percentage points ( \$108 million ) was as a result of the positive impact of currency translation. The remaining decrease was primarily related to cost benefits and dispositions. As a percentage of sales, selling, general and administrative expenses were 7.0% in the current period, compared to 7.0% in the year-ago period.

Adjusted operating income (Non-GAAP measure) for the nine months ended May 31, 2017 and May 31, 2016

Pharmaceutical Wholesale division's adjusted operating income for the nine months ended May 31, 2017 , which included \$238 million from the Company's share of adjusted equity earnings in AmerisourceBergen, increase d 40.6 % to \$703 million . Adjusted operating income was negatively impacted by 11.8 percentage points ( \$59 million ) as a result of currency translation.

Excluding the contribution from the Company's share of adjusted equity earnings in AmerisourceBergen and the negative impact of currency translation, adjusted operating income increase d 6.3% over the year-ago period. See "--Non-GAAP Measures" below for a reconciliation to the most directly comparable GAAP measure.

**NON-GAAP MEASURES**

The following information provides reconciliations of the supplemental non-GAAP financial measures, as defined under the rules of the Securities and Exchange Commission, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP.

These supplemental non-GAAP financial measures are presented because our management has evaluated our financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of our business from period to period and trends in our historical operating results. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

The Company also presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year. The Company presents such constant currency financial information because it has significant operations outside of the United States reporting in currencies other than the U.S. dollar and such presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.

	(in millions)				
	Three months ended May 31, 2017				
	Retail Pharmacy USA	Retail Pharmacy International	Pharmaceutical Wholesale	Eliminations	Walgreens Boots Alliance, Inc.
Operating income (GAAP)	\$ 1,170	\$ 142	\$ 200	\$ 5	\$ 1,517
Cost transformation	129	26	16	—	171
Acquisition-related amortization	38	25	20	—	83
LIFO provision	97	—	—	—	97
Adjustments to equity earnings in AmerisourceBergen	—	—	17	—	17
Acquisition-related costs	29	—	—	—	29
Adjusted operating income (Non-GAAP measure)	<u>\$ 1,463</u>	<u>\$ 193</u>	<u>\$ 253</u>	<u>\$ 5</u>	<u>\$ 1,914</u>

	(in millions)				
	Three months ended May 31, 2016				
	Retail Pharmacy USA	Retail Pharmacy International	Pharmaceutical Wholesale	Eliminations	Walgreens Boots Alliance, Inc.
Operating income (GAAP)	\$ 1,169	\$ 223	\$ 146	\$ (5)	\$ 1,533
Cost transformation	60	6	7	—	73
Acquisition-related amortization	46	29	21	—	96
LIFO provision	92	—	—	—	92
Adjustments to equity earnings in AmerisourceBergen	—	—	5	—	5
Acquisition-related costs	15	—	—	—	15
Adjusted operating income (Non-GAAP measure)	<u>\$ 1,382</u>	<u>\$ 258</u>	<u>\$ 179</u>	<u>\$ (5)</u>	<u>\$ 1,814</u>

	(in millions)				
	Nine months ended May 31, 2017				
	Retail Pharmacy USA	Retail Pharmacy International	Pharmaceutical Wholesale	Eliminations	Walgreens Boots Alliance, Inc.
Operating income (GAAP)	\$ 3,395	\$ 522	\$ 525	\$ 1	\$ 4,443
Cost transformation	517	51	24	—	592
Acquisition-related amortization	113	75	59	—	247
LIFO provision	204	—	—	—	204
Adjustments to equity earnings in AmerisourceBergen	—	—	95	—	95
Acquisition-related costs	75	—	—	—	75
Adjusted operating income (Non-GAAP measure)	<u>\$ 4,304</u>	<u>\$ 648</u>	<u>\$ 703</u>	<u>\$ 1</u>	<u>\$ 5,656</u>

(in millions)

	Nine months ended May 31, 2016				
	<b>Retail Pharmacy USA</b>	<b>Retail Pharmacy International</b>	<b>Pharmaceutical Wholesale</b>	<b>Eliminations</b>	<b>Walgreens Boots Alliance, Inc.</b>
Operating income (GAAP)	\$ 3,626	\$ 824	\$ 423	\$ (12)	\$ 4,861
Cost transformation	170	14	7	—	191
Acquisition-related amortization	143	70	65	—	278
LIFO provision	206	—	—	—	206
Adjustments to equity earnings in AmerisourceBergen	—	—	5	—	5
Acquisition-related costs	82	—	—	—	82
Asset impairment	\$ 30	\$ —	\$ —	\$ —	\$ 30
Adjusted operating income (Non-GAAP measure)	\$ 4,257	\$ 908	\$ 500	\$ (12)	\$ 5,653

	(in millions, except per share amounts)			
	Three months ended		Nine months ended	
	May 31, 2017	May 31, 2016	May 31, 2017	May 31, 2016
Net earnings attributable to Walgreens Boots Alliance, Inc. (GAAP)	\$ 1,162	\$ 1,103	\$ 3,276	\$ 3,143
Adjustments to operating income:				
Cost transformation <sup>1</sup>	171	73	592	191
Acquisition-related amortization <sup>1</sup>	83	96	247	278
LIFO provision <sup>1</sup>	97	92	204	206
Adjustments to equity earnings in AmerisourceBergen <sup>1</sup>	17	5	95	5
Acquisition-related costs <sup>1</sup>	29	15	75	82
Asset impairment <sup>1</sup>	—	—	—	30
Total adjustments to operating income	397	281	1,213	792
Adjustments to other income (expense):				
Net investment hedging (gain) loss <sup>1</sup>	1	(4)	15	(37)
Decrease in fair market value of AmerisourceBergen warrants <sup>1</sup>	—	259	—	845
Impact of change in accounting method for AmerisourceBergen equity investment <sup>1</sup>	—	(268)	—	(268)
Total adjustments to other income (expense)	1	(13)	15	540
Adjustments to interest expense, net:				
Prefunded interest expenses <sup>1</sup>	34	4	123	4
Total adjustments to interest expense, net	34	4	123	4
Adjustments to income tax provision:				
United Kingdom tax rate change <sup>2</sup>	—	—	(77)	(178)
Tax impact of adjustments <sup>3</sup>	(153)	(87)	(432)	(458)
Total adjustments to income tax provision	(153)	(87)	(509)	(636)
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)	\$ 1,441	\$ 1,288	\$ 4,118	\$ 3,843
Diluted net earnings per common share (GAAP)	\$ 1.07	\$ 1.01	\$ 3.02	\$ 2.88
Adjustments to operating income	0.37	0.26	1.12	0.73
Adjustments to other income (expense)	—	(0.01)	0.01	0.49
Adjustments to interest expense, net	0.03	—	0.11	—
Adjustments to income tax provision	(0.14)	(0.08)	(0.47)	(0.58)
Adjusted diluted net earnings per common share (Non-GAAP measure)	\$ 1.33	\$ 1.18	\$ 3.79	\$ 3.52
Weighted average common shares outstanding, diluted	1,082.6	1,088.2	1,085.5	1,091.7

<sup>1</sup> Presented on a pre-tax basis. The comparable prior period has been recast accordingly to reflect the tax impact of adjustments as a single adjustment. There has been no change in net earnings attributable to Walgreens Boots Alliance, Inc., diluted net earnings per share, adjusted net earnings attributable to Walgreens Boots Alliance, Inc. or adjusted net earnings per share from those previously reported.

<sup>2</sup> Discrete tax-only items.

<sup>3</sup> Represents the adjustment to the GAAP basis tax provision commensurate with non-GAAP adjustments.

### **LIQUIDITY AND CAPITAL RESOURCES**

Cash and cash equivalents were \$12.3 billion (including \$2.2 billion in non-U.S. jurisdictions) as of May 31, 2017, compared to \$3.3 billion (including \$1.5 billion in non-U.S. jurisdictions) at May 31, 2016. Short-term investment objectives are primarily to minimize risk and maintain liquidity. To attain these objectives, investment limits are placed on the amount, type and issuer of securities. Investments are principally in U.S. Treasury money market funds and AAA-rated money market funds.

Our long-term capital policy is to maintain a strong balance sheet and financial flexibility; reinvest in our core strategies; invest in strategic opportunities that reinforce our core strategies and meet return requirements; and return surplus cash flow to shareholders in the form of dividends and share repurchases over the long term.

Cash provided by operations and the issuance of debt are the principal sources of funds for expansion, investments, acquisitions, remodeling programs, dividends to shareholders and stock repurchases. Net cash provided by operating activities for the nine months ended May 31, 2017 was \$5,237 million, compared to \$5,189 million for the year-ago period. The increase in cash provided by operating activities was primarily due to improved working capital management, with higher cash inflows from changes in inventories. Increases in cash inflows on inventories resulted primarily from Retail Pharmacy USA inventory management initiatives related to simplified retail product offering, promotional efficiencies and lower brand name drug inflation.

Net cash used for investing activities was \$452 million for the nine months ended May 31, 2017, compared to \$1,961 million used in the year-ago period. Business acquisitions in the nine months ended May 31, 2017 were \$63 million compared to \$115 million for the year-ago period. Business acquisitions in the year-ago period were primarily the acquisition of an international beauty brand and the purchase of prescription files. The year-ago period included an investment in AmerisourceBergen of \$1,169 million following the exercise of warrants.

For the nine months ended May 31, 2017, additions to property, plant and equipment were \$912 million compared to \$904 million in the year-ago period. Capital expenditures by reporting segment were as follows:

	<b>Nine months ended</b>	
	<b>May 31, 2017</b>	<b>May 31, 2016</b>
Retail Pharmacy USA	\$ 556	\$ 523
Retail Pharmacy International	279	315
Pharmaceutical Wholesale	77	66
Total	<u>\$ 912</u>	<u>\$ 904</u>

Significant capital expenditures primarily relate to investments in our stores and information technology projects.

Additionally, investing activities for the nine months ended May 31, 2017 included proceeds related to sale-leaseback transactions of \$436 million, compared to \$60 million in the year-ago period.

Net cash used for financing activities for the nine months ended May 31, 2017 was \$2,333 million, compared to net cash used of \$2,894 million in the year-ago period. We repurchased shares as part of the \$1 billion stock repurchase program described below and to support the needs of the employee stock plans totaling \$1,457 million in the nine months ended May 31, 2017, compared to \$1,152 million in shares repurchased in the nine months ended May 31, 2016. Proceeds related to employee stock plans were \$174 million during the nine months ended May 31, 2017, compared to \$175 million for the nine months ended May 31, 2016. Cash dividends paid were \$1,228 million during the nine months ended May 31, 2017, compared to \$1,174 million for the same period a year ago. We currently intend to continue to maintain a long-term dividend payout ratio target of approximately 30 to 35 percent of adjusted net earnings attributable to Walgreens Boots Alliance.

In April 2017, Walgreens Boots Alliance authorized a stock repurchase program (the "\$1 billion stock repurchase program"), which authorized the repurchase of up to \$1.0 billion of Walgreens Boots Alliance common stock prior to the program's expiration on December 31, 2017. In May 2017, the Company completed the \$1 billion stock repurchase program. See Part II, Item 2 below for additional information. In June 2017, Walgreens Boots Alliance authorized a new stock repurchase program (the "\$5 billion stock repurchase program"), which authorizes the repurchase of up to \$5.0 billion of Walgreens Boots Alliance common stock prior to the program's expiration on August 31, 2018. We determine the timing and amount of repurchases based on our assessment of various factors, including prevailing market conditions, alternate uses of capital, liquidity and the

economic environment. We have repurchased, and may from time to time in the future repurchase, shares on the open market through Rule 10b5-1 plans, which enable us to repurchase shares at times when we otherwise might be precluded from doing so under insider trading laws.

We periodically borrow under our commercial paper program and may continue to borrow under it in future periods. There were no commercial paper borrowings outstanding as of May 31, 2017 or August 31, 2016, respectively. The Company had no activity under its commercial paper program for the nine months ended May 31, 2017. The Company had average daily short-term borrowings of \$18 million of commercial paper outstanding at a weighted average interest rate of 0.66% for the nine month period ended May 31, 2016.

*Terminated acquisition of Rite Aid and related matters*

Pursuant to the Termination Agreement, the Company agreed to pay Rite Aid the termination fee of \$325 million, which amount the Company plans to pay on or before June 30, 2017, in full satisfaction of any amounts required to be paid by the Company under the Merger Agreement and other Transaction Documents. In connection with the termination of the Fred's Asset Purchase Agreement, the Company agreed to reimburse certain of Fred's transaction costs in an amount not to exceed \$25 million in full satisfaction of any amounts required to be paid by the Company under the Fred's Asset Purchase Agreement. The Company expects to pay the applicable amount during the fourth quarter of fiscal 2017.

On June 1, 2016, Walgreens Boots Alliance issued in an underwritten public offering \$1.2 billion of 1.750% notes due 2018 (the "2018 notes"), \$1.5 billion of 2.600% notes due 2021 (the "2021 notes"), \$0.8 billion of 3.100% notes due 2023 (the "2023 notes"), \$1.9 billion of 3.450% notes due 2026 (the "2026 notes") and \$0.6 billion of 4.650% notes due 2046 (the "2046 notes"). Because the merger with Rite Aid was not consummated on or prior to June 1, 2017, the 2018 notes, the 2021 notes and the 2023 notes (but not the 2026 notes or 2046 notes, which remain outstanding in accordance with their respective terms) were redeemed on June 5, 2017 under the special mandatory redemption terms of the indenture governing such notes. Walgreens Boots Alliance was required to redeem all of the 2018 notes, the 2021 notes and the 2023 notes then outstanding, at a special mandatory redemption price equal to 101% of the aggregate principal amount of such notes, plus accrued and unpaid interest of approximately \$1 million to, but excluding, the date of redemption. Walgreens Boots Alliance used cash on hand to fund the special mandatory redemption. As a result of the special mandatory redemption of the 2018 notes, the 2021 notes and the 2023 notes, in the fourth quarter of fiscal 2017, the Company will recognize as interest expense on a pretax basis the entire \$13 million unamortized portion of the related debt issuance costs and debt issuance discounts and the entire \$35 million redemption premium paid on such notes upon such redemption. The 2026 notes and 2046 notes (which are not subject to special mandatory redemption) are subject to redemption in certain circumstances.

On February 22, 2017, Walgreens Boots Alliance entered into (a) a \$4.8 billion unsecured term loan facility with the lenders party thereto (the "Syndicated Credit Agreement") and (b) a \$1.0 billion unsecured term loan facility with Sumitomo Mitsui Banking Corporation, as lender and administrative agent (the "Sumitomo Credit Agreement" and, together with the Syndicated Credit Agreement, the "2017 Term Loan Credit Agreements"). The obligations of the lenders party to each of the 2017 Term Loan Credit Agreements to fund the loans thereunder were to become effective upon the date of closing of the transactions contemplated by the Merger Agreement. Each of the 2017 Term Loan Credit Agreements and the commitments contemplated thereby terminated on June 28, 2017 upon the termination of the Merger Agreement. See "-Introduction and segments - terminated acquisition of Rite Aid and related matters" above. Upfront fees paid to date in connection with the 2017 Term Loan Credit Agreements totaled \$4.6 million. As of May 31, 2017, there were no borrowings under either of the 2017 Term Loan Credit Agreements.

*2017 Revolving Credit Agreement*

On February 1, 2017, Walgreens Boots Alliance entered into a \$1.0 billion revolving credit facility (the "2017 Revolving Credit Agreement") with the lenders from time to time party thereto. Walgreens Boots Alliance will be the borrower under the 2017 Revolving Credit Agreement, which terminates on the earlier of (a) 364 days following the effective date thereof, subject to the extension thereof pursuant to provisions specified in the Revolving Credit Agreement, and (b) the date of termination in whole of the aggregate commitment pursuant to the Revolving Credit Agreement. The ability of Walgreens Boots Alliance to request the making of loans under the 2017 Revolving Credit Agreement is subject to the satisfaction (or waiver) of certain customary conditions set forth therein. Borrowings under the 2017 Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance's option, the alternate base rate or the reserve adjusted Eurocurrency rate, in each case, plus an applicable margin calculated based on Walgreens Boots Alliance's credit ratings. Upfront fees paid to date in connection with the 2017 Revolving Credit Agreement totaled \$0.5 million. In addition, Walgreens Boots Alliance will also pay to the lenders under the 2017 Revolving Credit Agreement certain customary fees, including a commitment fee on the daily actual excess of each such lender's commitment over such lender's outstanding credit exposure under the 2017 Revolving Credit Agreement, which commitment fee is earned and payable quarterly. As of May 31, 2017, there were no borrowings under the 2017 Revolving Credit Agreement.

*Debt covenants*

The Company's credit facilities contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00. The credit facilities contain various other customary covenants. As of May 31, 2017, the Company was in compliance with all such covenants.

As of June 28, 2017, the credit ratings of Walgreens Boots Alliance were:

Rating agency	Long-term debt rating	Commercial paper rating	Outlook
Fitch	BBB	F2	Stable
Moody's	Baa2	P-2	On review for downgrade
Standard & Poor's	BBB	A-2	Negative

In assessing our credit strength, each credit rating agency considers various factors including our business model, capital structure, financial policies and financial performance. There can be no assurance that any particular rating will be assigned or maintained. Our credit ratings impact our borrowing costs, access to capital markets and operating lease costs. The rating agency ratings are not recommendations to buy, sell or hold our debt securities or commercial paper. Each rating may be subject to revision or withdrawal at any time by the assigning rating agency and should be evaluated independently of any other rating.

Pursuant to our arrangements with AmerisourceBergen, we have the right, but not the obligation, to increase our minority equity position in AmerisourceBergen over time, as described under "--AmerisourceBergen Corporation Relationship" above. As of May 31, 2017, the Company owned 56,854,867 AmerisourceBergen common shares representing approximately 26% of the outstanding AmerisourceBergen common stock. This includes a total of approximately 11.5 million shares of AmerisourceBergen that we purchased in the open market. Share purchases may be made from time to time in open market transactions or pursuant to instruments and plans complying with Rule 10b5-1. Our ability to invest in equity in AmerisourceBergen above certain thresholds is subject to the receipt of regulatory approvals.

We believe that cash flow from operations, availability under our existing credit facilities and arrangements, current cash and investment balances and our ability to obtain other financing, if necessary, will provide adequate cash funds for foreseeable working capital needs, capital expenditures at existing facilities, acquisitions, dividend payments and debt service obligations for at least the next 12 months. Our cash requirements are subject to change as business conditions warrant and opportunities arise. The timing and size of any new business ventures or acquisitions that we may complete may also impact our cash requirements.

See Item 3. Qualitative and quantitative disclosures about market risk below for a discussion of certain financing and market risks.

**OFF-BALANCE SHEET ARRANGEMENTS**

We do not have any unconsolidated special purpose entities and, except as described herein, we do not have significant exposure to any off-balance sheet arrangements. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have: (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

As of May 31, 2017, we have issued \$330 million in letters of credit, primarily related to insurance obligations. We also had \$45 million of guarantees to various suppliers outstanding as of May 31, 2017. We remain secondarily liable on 70 leases. The maximum potential undiscounted future payments related to these leases was \$330 million as of May 31, 2017.

**CONTRACTUAL OBLIGATIONS AND COMMITMENTS**

Other than our obligations under the Merger Agreement and the transactions contemplated thereby, there have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations disclosed in the Walgreens Boots Alliance Annual Report on Form 10-K for the year ended August 31, 2016.

**CRITICAL ACCOUNTING POLICIES**

The consolidated financial statements are prepared in accordance with GAAP and include amounts based on management's prudent judgments and estimates. Actual results may differ from these estimates. Management believes that any reasonable deviation from those judgments and estimates would not have a material impact on our consolidated financial position or

results of operations. To the extent that the estimates used differ from actual results, however, adjustments to the statement of earnings and corresponding balance sheet accounts would be necessary. These adjustments would be made in future periods. For a discussion of our significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2016. Some of the more significant estimates include business combinations, goodwill and indefinite-lived intangible asset impairment, vendor allowances, liability for closed locations, cost of sales and inventory, equity method investments, pension and postretirement benefits and income taxes. There have been no significant changes in those accounting policies.

#### **NEW ACCOUNTING PRONOUNCEMENTS**

A discussion of new accounting pronouncements is described in note 17, New accounting pronouncements in Item 1. Consolidated Condensed Financial Statements (Unaudited) of this Current Report on Form 10-Q and is incorporated herein by reference.

#### **CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This report and other documents that we file or furnish with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management's assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases or written statements, on the Company's website or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls, conference calls and other communications. Some of such forward-looking statements may be based on certain data and forecasts relating to our business and industry that we have obtained from internal surveys, market research, publicly available information and industry publications. Industry publications, surveys and market research generally state that the information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. Statements that are not historical facts are forward-looking statements, including, without limitation, those regarding estimates of and goals for future financial and operating performance as well as forward-looking statements concerning the expected execution and effect of our business strategies, our cost-savings and growth initiatives and restructuring activities and the amounts and timing of their expected impact, the termination of the Merger Agreement with Rite Aid and the transactions contemplated thereby (including the termination of the divestiture agreement to sell certain Rite Aid stores and assets to Fred's, Inc.) and their possible effects, our pending Asset Purchase Agreement with Rite Aid and the transactions contemplated thereby and their possible timing and effects, our commercial agreement with AmerisourceBergen, the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects, estimates of the impact of developments on our earnings, earnings per share and other financial and operating metrics, cough, cold and flu season, prescription volume, pharmacy sales trends, prescription margins, changes in generic prescription drug prices, retail margins, number and location of new store openings, network participation, vendor, payer and customer relationships and terms, possible new contracts or contract extensions, the proposed withdrawal of the United Kingdom from the European Union and its possible effects, competition, economic and business conditions, outcomes of litigation and regulatory matters, the level of capital expenditures, industry trends, demographic trends, growth strategies, financial results, cost reduction initiatives, impairment or other charges, acquisition and joint venture synergies, competitive strengths and changes in legislation or regulations. Words such as "expect," "likely," "outlook," "forecast," "preliminary," "would," "could," "should," "can," "will," "project," "intend," "plan," "goal," "guidance," "target," "aim," "continue," "sustain," "synergy," "on track," "on schedule," "headwind," "tailwind," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words and similar expressions are intended to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially from those indicated or anticipated, including, but not limited to, those relating to the impact of private and public third-party payers' efforts to reduce prescription drug reimbursements, fluctuations in foreign currency exchange rates, the timing and magnitude of the impact of branded to generic drug conversions and changes in generic drug prices, our ability to realize synergies and achieve financial, tax and operating results in the amounts and at the times anticipated, supply arrangements including our commercial agreement with AmerisourceBergen, the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects, our equity method investment in AmerisourceBergen, the occurrence of any event, change or other circumstance that could give rise to the termination, cross-termination or modification of any of our contractual obligations, the amount of costs, fees, expenses and charges incurred in connection with strategic transactions, whether the costs associated with restructuring activities will exceed estimates, our ability to realize expected savings and benefits from cost-savings initiatives, restructuring activities and acquisitions in the amounts and at the times anticipated, the timing and amount of any impairment or other charges, the timing and severity of cough, cold and flu season, changes in management's assumptions, the risks associated with governance and control matters, the ability to retain key personnel, changes in economic and business conditions generally or in particular markets in which we participate, changes in financial markets and interest rates, the risks



associated with international business operations, including the risks associated with the proposed withdrawal of the United Kingdom from the European Union, the risk of unexpected costs, liabilities or delays, changes in vendor, customer and payer relationships and terms, including changes in network participation and reimbursement terms, risks of inflation in the cost of goods, risks associated with the operation and growth of our customer loyalty programs, competition, risks associated with new business areas and activities, risks associated with acquisitions, divestitures, joint ventures and strategic investments, including those relating to the ability of the parties to satisfy the closing conditions (including, without limitation, the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) and consummate the pending acquisition of certain Rite Aid assets and related matters on a timely basis or at all, the risks associated with the integration of complex businesses, the risks associated with the termination of our Merger Agreement with Rite Aid and the transactions contemplated thereby (including the divestiture transaction to sell certain Rite Aid stores and assets to Fred's, Inc.) and the effects thereof, outcomes of legal and regulatory matters, including with respect to regulatory review and actions in connection with the pending acquisition of certain Rite Aid assets and related matters, and changes in laws, regulations or interpretations thereof. These and other risks, assumptions and uncertainties are described in Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended August 31, 2016, in Item 1A. "Risk factors" in this report and in other documents that we file or furnish with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date the statement is made, whether as a result of new information, future events, changes in assumptions or otherwise.

**Item 3. Quantitative and qualitative disclosure about market risk**

***Interest rate risk***

We are exposed to interest rate volatility with regard to existing debt issuances. Primary exposures include U.S. Treasury rates, LIBOR and commercial paper rates. From time to time, we use interest rate swaps and forward-starting interest rate swaps to hedge our exposure to the impact of interest rate changes on existing debt and future debt issuances respectively, to reduce the volatility of our financing costs and, based on current and projected market conditions, achieve a desired proportion of fixed versus floating-rate debt. Generally under these swaps, we agree with a counterparty to exchange the difference between fixed-rate and floating-rate interest amounts based on an agreed upon notional principal amount.

We also use interest rate caps to protect from rising interest rates on existing floating-rate debt. Information regarding our interest rate swaps, forward starting interest rate swaps, and interest rate caps transactions are set forth in note 8. Financial instruments to our unaudited Consolidated Condensed Financial Statements. These financial instruments are sensitive to changes in interest rates. On May 31, 2017, we had approximately \$1.7 billion in long-term debt obligations that had floating interest rates. A one percentage point increase or decrease in interest rates for the various debt held by us would increase or decrease the annual interest expense we recognize and the cash we pay for interest expense on long-term debt obligations by approximately \$17 million. The amounts exclude the impact of any associated interest rate swaps, forward starting interest rate swaps and interest rate caps.

***Foreign currency exchange rate risk***

We are exposed to fluctuations in foreign currency exchange rates, primarily with respect to the British Pound Sterling and Euro, and certain other foreign currencies, including the Mexican Peso, Chilean Peso, Norwegian Krone and Turkish Lira which may affect our net investment in foreign subsidiaries and may cause fluctuations in cash flows related to foreign denominated transactions. We are also exposed to the translation of foreign currency earnings to the U.S. dollar. We enter into foreign currency forward contracts to hedge against the effect of exchange rate fluctuations on non-functional currency cash flows of certain entities denominated in foreign currencies. These transactions are almost exclusively less than 12 months in maturity. In addition, we enter into foreign currency forward contracts that are not designated in hedging relationships to offset, in part, the impacts of certain intercompany activities (primarily associated with intercompany financing transactions). As circumstances warrant, we also use basis swaps as hedging instruments to hedge portions of our net investments in foreign operations. The foreign currency derivative instruments are sensitive to changes in exchange rates. A 1% increase or decrease in foreign currency exchange rates versus the U.S. dollar would increase or decrease our pre-tax income by approximately \$10 million due to changes in the value of foreign currency derivative instruments. Excluded from the computation were anticipated transactions, foreign currency trade payables and receivables, and net investments in foreign subsidiaries, which the abovementioned instruments are intended to partially hedge.

**Item 4. Controls and procedures**

**Evaluation of disclosure controls and procedures**

Management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of the Company's management, including its Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"). Based upon the controls evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the SEC, and that such information is accumulated and communicated to management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

**Changes in internal control over financial reporting**

In connection with the evaluation pursuant to Exchange Act Rule 13a-15(d) of the Company's internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) by the Company's management, including its CEO and CFO, no changes during the three months ended May 31, 2017 were identified that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Inherent limitations on effectiveness of controls**

Our management, including the CEO and CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be

faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

## Part II. Other Information

### Item 1. **Legal proceedings**

The information in response to this item is incorporated herein by reference to note 10, Commitments and contingencies of the Consolidated Condensed Financial Statements of this Quarterly Report.

### Item 1A. **Risk factors**

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Item 1A. “Risk factors” in the Walgreens Boots Alliance Annual Report on Form 10-K for the year ended August 31, 2016 as amended and supplemented by the risk factors set forth below, which could materially affect our business, financial condition or future results. The risk factors in the Form 10-K for the year ended August 31, 2016 captioned “We may not be able to successfully or timely complete the pending acquisition of Rite Aid” and “If we complete our pending acquisition of Rite Aid, we may not realize the anticipated benefits of the transaction, which could adversely impact our results of operations” are hereby deleted. In addition, the second through fifth sentences of the second paragraph of the risk factor captioned “We have significant outstanding debt; our debt and associated payment obligations could significantly increase in the future if we incur additional debt and do not retire existing debt” are hereby deleted.

#### **We may not be able to successfully or timely complete the pending acquisition of certain Rite Aid assets.**

Risks and uncertainties related to our pending acquisition of 2,186 stores and three distribution centers from Rite Aid include, among others: the occurrence of any event, change or other circumstance that could give rise to the termination of the Asset Purchase Agreement including that regulatory or other approvals required for the transaction are not obtained; that litigation may be filed which could prevent or delay the transaction; and that uncertainty regarding the transaction may adversely affect relationships with suppliers, payers, customers and other third parties. Completion of the transaction is subject to the satisfaction of certain conditions set forth in the Asset Purchase Agreement, including the expiration or termination of applicable waiting periods (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary conditions. We will be unable to complete the pending acquisition of these Rite Aid assets until each of the conditions to closing is either satisfied or waived. In deciding whether or not to object to the transaction, regulatory agencies have broad discretion in administering the applicable governing regulations. We can provide no assurance that we will obtain the necessary approvals on any particular timetable or at all, or that any conditions that are imposed in connection with such review would not diminish the anticipated benefits of the transaction or result in the termination of the transaction. We have incurred and will continue to incur significant costs, expenses and fees for professional services and other transaction costs in connection with the pending transaction, as well as the diversion of management resources, for which we will receive little or no benefit if the closing of the transaction does not occur.

#### **If we complete the pending acquisition of certain Rite Aid assets pursuant to the Asset Purchase Agreement, we may not realize the anticipated benefits of the transaction, which could adversely impact our results of operations.**

We entered into the Asset Purchase Agreement to acquire certain Rite Aid stores and distribution centers with the expectation that the transaction will result in various benefits, including, among other things, cost savings and operating efficiencies. The achievement of the anticipated benefits of the transaction is subject to a number of uncertainties, including whether the acquired assets can be integrated into our business in an efficient and effective manner, the possibility of faulty assumptions underlying expectations regarding potential synergies and the integration process, unforeseen expenses or delays, and competitive factors in the marketplace. If the acquisition of Rite Aid assets pursuant to the Asset Purchase Agreement is completed, we can provide no assurance that the anticipated benefits of the transaction, including cost savings and synergies, will be fully realized in the time frame anticipated or at all; the costs or difficulties related to the integration of the acquired assets into our business and operations will not be greater than expected; unanticipated costs, charges and expenses will not result from the transaction; litigation relating to the transaction will not be filed; and the transaction will not cause disruption to the parties’ business and operations and relationships with employees and suppliers, payers, customers and other third parties. If one or more of these risks are realized, it could have a material adverse impact on our operating results.

We could also encounter unforeseen transaction and integration-related costs or other circumstances, such as unforeseen liabilities or other issues resulting from the transaction. Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased synergies and the diversion of management time and attention, which could adversely impact our agility to respond to market opportunities and our ability to timely identify and implement other strategic actions. If we are unable to achieve our objectives within the anticipated time frame, or at all, the expected benefits may not be realized fully or at all, or may take longer to realize than expected, which could have a material adverse impact on our business operations, financial condition and results of operations. In addition, we have incurred significant transaction costs related to the pending transaction and, if it is consummated, we will continue to incur significant integration and related costs as we integrate the acquired Rite Aid assets. These integration and acquisition-related costs, including legal, accounting, financial and tax advisory and other fees and costs, may be higher than expected and some of these costs may be material.

**Item 2. Unregistered sales of equity securities and use of proceeds**

(c) The following table provides information about purchases by the Company during the quarter ended May 31, 2017 of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act. Subject to applicable law, share purchases may be made from time to time in open market transactions, privately negotiated transactions including accelerated share repurchase agreements, or pursuant to instruments and plans complying with Rule 10b5-1.

<b>Issuer purchases of equity securities</b>				
<b>Period</b>	<b>Total number of shares purchased</b>	<b>Average price paid per share</b>	<b>Total number of shares purchased as part of publicly announced repurchase programs <sup>1</sup></b>	<b>Approximate dollar value of shares that may yet be purchased under the plans or program <sup>1</sup></b>
03/01/17 – 03/31/17	—	\$ —	—	\$ —
04/01/17 – 04/30/17	6,329,364	83.50	6,329,364	471,493,961
05/01/17 – 05/31/17	5,490,591	85.87	5,490,591	—
<b>Total</b>	<b>11,819,955</b>	<b>\$ 84.60</b>	<b>11,819,955</b>	<b>\$ —</b>

<sup>1</sup> In April 2017, Walgreens Boots Alliance authorized a stock repurchase program which authorized the repurchase of up to \$1.0 billion of Walgreens Boots Alliance common stock prior to the program's expiration on December 31, 2017. In May 2017, the Company completed this \$1.0 billion stock repurchase program. In June 2017, Walgreens Boots Alliance authorized a new stock repurchase program, which authorizes the repurchase of up to \$5.0 billion of Walgreens Boots Alliance common stock prior to the program's expiration on August 31, 2018.

**Item 6. Exhibits**

The agreements included as exhibits to this report are included to provide information regarding their terms and not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement that were made solely for the benefit of the other parties to the applicable agreement, and:

- should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;
- may have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;
- may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and
- were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time.

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>	<b><u>SEC Document Reference</u></b>
3.1	Amended and Restated Certificate of Incorporation of Walgreens Boots Alliance, Inc.	Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.'s Current Report on Form 8-K12B (File No. 001-36759) filed with the SEC on December 31, 2014.
3.2	Amended and Restated Bylaws of Walgreens Boots Alliance, Inc.	Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.'s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on June 10, 2016.
10.1*	Extension, dated as of March 27, 2017, to Assignment Letter between Alexander Gourlay and Walgreens Boots Alliance Services Limited.	Incorporated by reference to Exhibit 10.6 to Walgreens Boots Alliance, Inc.'s Quarterly Report on Form 10-Q for the quarter ended February 28, 2017 (File No. 1-36759) filed with the SEC on April 5, 2017.
12	Computation of Ratio of Earnings to Fixed Charges.	Filed herewith.
31.1	Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith.
31.2	Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith.
32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.	Furnished herewith.
32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.	Furnished herewith.
101.INS	XBRL Instance Document	Filed herewith.
101.SCH	XBRL Taxonomy Extension Schema Document	Filed herewith.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document	Filed herewith.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.

---

\* Management contract or compensatory plan or arrangement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Walgreens Boots Alliance, Inc.

(Registrant)

Dated: June 29, 2017

/s/ George R. Fairweather

George R. Fairweather

Executive Vice President and Global Chief Financial Officer

Dated: June 29, 2017

/s/ Kimberly R. Scardino

Kimberly R. Scardino

Senior Vice President, Global Controller and Chief Accounting Officer

(Principal Accounting Officer)

**Walgreens Boots Alliance, Inc.**  
**Computation of Historical Ratios of Earnings to Fixed Charges (a)**  
(in millions, except ratio data)

	Nine months ended		Twelve Months Ended,				
	May 31, 2017	2016	2015	2014	2013	2012	
Income before income tax provision	\$ 3,921	\$ 5,144	\$ 5,311	\$ 3,557	\$ 4,047	\$ 3,376	
Add:							
Minority Interests	—	—	—	—	5	—	
Fixed Charges	1,777	2,367	2,054	1,376	1,383	1,260	
Amortization of capitalized interest	—	—	1	6	7	6	
Less:							
Equity earnings	(90)	(37)	(315)	(617)	(496)	—	
Capitalized interest	—	—	(1)	(6)	(7)	(9)	
Earnings as defined	<u>\$ 5,608</u>	<u>\$ 7,474</u>	<u>\$ 7,050</u>	<u>\$ 4,316</u>	<u>\$ 4,939</u>	<u>\$ 4,633</u>	
Interest expense, net of capitalized interest	\$ 542	\$ 628	\$ 632	\$ 168	\$ 193	\$ 94	
Capitalized interest	—	—	1	6	7	9	
Portions of rentals representative of the interest factor	1,235	1,739	1,421	1,202	1,183	1,157	
Fixed charges as defined	<u>\$ 1,777</u>	<u>\$ 2,367</u>	<u>\$ 2,054</u>	<u>\$ 1,376</u>	<u>\$ 1,383</u>	<u>\$ 1,260</u>	
Ratio of earnings to fixed charges	3.16	3.16	3.43	3.14	3.57	3.68	

(a) For the purpose of computing these ratios, "earnings" consist of earnings before income tax provision and before adjustment for income or loss from equity investees, interest, distributed income of equity-method investees, and the portions of rentals representative of the interest factor. "Fixed charges" consist of interest expense (which includes amortization of capitalized debt issuance costs), capitalized interest and the portions of rentals representative of the interest factor.



## CERTIFICATION

I, Stefano Pessina, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/

Stefano Pessina

Chief Executive Officer

Date: June 29, 2017

---

Stefano Pessina

## CERTIFICATION

I, George Fairweather, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/

George Fairweather

Global Chief Financial Officer

Date: June 29, 2017

---

George Fairweather

**CERTIFICATION PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  
(18 U.S.C. SECTION 1350)**

In connection with the Quarterly Report of Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), on Form 10-Q for the quarter ended May 31, 2017 as filed with the Securities and Exchange Commission (the "Report"), I, Stefano Pessina, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Stefano Pessina  
Stefano Pessina  
Chief Executive Officer  
Dated: June 29, 2017

A signed original of this written statement required by Section 906 has been provided to Walgreens Boots Alliance, Inc. and will be retained by Walgreens Boots Alliance, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

**CERTIFICATION PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  
(18 U.S.C. SECTION 1350)**

In connection with the Quarterly Report of Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), on Form 10-Q for the quarter ended May 31, 2017 as filed with the Securities and Exchange Commission (the "Report"), I, George Fairweather, Global Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ George Fairweather

George Fairweather

Global Chief Financial Officer

Dated: June 29, 2017

A signed original of this written statement required by Section 906 has been provided to Walgreens Boots Alliance, Inc. and will be retained by Walgreens Boots Alliance, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.